ClinicalTrials.gg
CompletedNCT01500551Updated Mar 23, 2026Results posted

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

A Phase 2/3 interventional study of Tofacitinib and Tofacitinib in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 104 sites in 19 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
302
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2013
with 1 other
Phase 2/3
Only one
of the 10
Registered
6th of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is one of 2 that started in 2013, is the only one in phase 2/3, and was the 6th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.

Read the detailed description

This is a Phase 2/3, long term, open-label, follow-up study. Subjects will have previously participated in qualifying/index JIA studies of tofacitinib. Those who have already completed such participation and enroll outside the 14 day window following completion of the End of Study (EOS) Visit of the qualifying/index study will participate in a screening Visit to determine eligibility. A Baseline Visit will then occur within 28 days after the Screening Visit. For subjects who are completing participation in a qualifying study of tofacitinib and enrolling on the same day of the EOS Visit of the qualifying/index study, the EOS Visit of the qualifying/index study can be combined with the Screening and Baseline Visits for this study. The subjects who enroll within the 14 day window following completion of the EOS Visit of the qualifying/index study will participate in a combined Screening and Baseline Visit for this study. After the Baseline Visit, visits will occur at 1 month (1 month=30 days) and 3 months, then every 3 months thereafter as long as the subject remains in the study.

Approximately 340 participants are projected to enroll into this open label extension study after completing a qualifying/index study in the JIA program.

For subjects who entered this study from the A3921103 and A3921104 qualifying/index studies, their participation in this study ends after the first marketing approval of tofacitinib for the treatment of polyarticular course Juvenile Idiopathic Arthritis (pJIA) in any country. This study will end once the last subject, and all other subjects, who entered from index study A3921165 have completed approximately 1 year in this study, or after the first marketing approval of tofacitinib for the treatment of systemic JIA, whichever comes first.

The total duration of an individual subject's participation may vary depending upon when they enter the trial.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Arthritis
  • Pediatric
  • Long-term
  • JIA
  • CP-690,550
  • tofacitinib
  • Xeljanz
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric subjects with JIA aged from 2 to less than 18 years who met entry criteria for the qualifying/index study and in the opinion of the investigator have sufficient evidence of JIA disease activity to warrant use of tofacitinib as a DMARD. Subjects turning 18 years of age during participation in the qualifying/index study or subsequently will be eligible for participation in this study.
  • The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug, as defined in Appendix 1, and is taking only those concomitant medications in doses and frequency allowed by the protocol.
  • Fertile male subjects and female subjects of who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be using a highly effective method of as outlined in this protocol throughout the study and for at least 28 days after the last dose of study medication.
  • Subjects must have previously completed participation in a qualifying study of tofacitinib for the treatment of JIA. Subjects who have required earlier discontinuation of treatment in a qualifying study for reasons other than tofacitinib related serious adverse events may be eligible.

Exclusion criteria

Exclusion Criteria:

  • persistent oligoarthritis, and undifferentiated JIA.
  • Infections:

    1. Chronic infections.
    2. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 3 months prior to the first dose of study drug.
    3. Any treated infections within 2 weeks of baseline visit.
    4. A subject known to be infected with (HIV), or virus.
    5. History of infected joint prosthesis with prosthesis still in situ.
  • History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Tofacitinib

    All patients will be in tofacitinib treatment group.

    Drug: Tofacitinib

Interventions

  • Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165) 5 mg BID Dose Level: Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml) Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution. Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing.

    Also known as: CP 690,550, Xeljanz

  • For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.

    Also known as: CP-690,550, Xeljanz

06

What researchers measure

Primary outcomes

  1. Number of Participants With Laboratory Test Abnormalities

    Parameters: Hematology (hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, prothrombin international normalized ratio, erythrocyte sedimentation rate), clinical chemistry (bilirubin, direct/indirect bilirubin, aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high and low density lipoprotein cholesterol, Friedewald estimation, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, C reactive protein), urinalysis (specific gravity, potential of hydrogen (pH), glucose/ protein/ hemoglobin/ erythrocytes/ leukocytes, ketones, leukocyte esterase, hyaline casts, bacteria). Number of participants with at least 1 laboratory abnormality are reported.

    Time frame: During study treatment (maximum up to 118 months)

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily had a causal relationship with the treatment or usage. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that met one or more of the following criteria: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. An TEAE was any AE that occurred following the start of study treatment in this study or increased in severity following the start of study treatment in this study. AE included both SAEs and all non-SAEs.

    Time frame: From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention)

  3. Absolute Values of Body Weight at Baseline

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: At Baseline

  4. Absolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 12

  5. Absolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 24

  6. Absolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 36

  7. Absolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 48

  8. Absolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 60

  9. Absolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 72

  10. Absolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84

    Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 84

  11. Absolute Value of Height at Baseline

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: At Baseline

  12. Absolute Value of Height at Month 12 and Its Change From Baseline at Month 12

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 12

  13. Absolute Value of Height at Month 24 and Its Change From Baseline at Month 24

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 24

  14. Absolute Value of Height at Month 36 and Its Change From Baseline at Month 36

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 36

  15. Absolute Value of Height at Month 48 and Its Change From Baseline at Month 48

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 48

  16. Absolute Value of Height at Month 60 and Its Change From Baseline at Month 60

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 60

  17. Absolute Value of Height at Month 72 and Its Change From Baseline at Month 72

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 72

  18. Absolute Value of Height at Month 84 and Its Change From Baseline at Month 84

    Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

    Time frame: Baseline, Month 84

  19. Number of Participants According to Tanner Stage at Baseline

    Pubertal development was measured using Tanner stage, by age group (2 to \<6 years, 6 to \<12 years, and 12 years or older) for males and females separately. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (fully developed breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes continue to enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size).

    Time frame: At Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap)

  20. Number of Participants With Shift in Tanner Stage From Baseline to Month 12

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 12. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 12

  21. Number of Participants With Shift in Tanner Stage From Baseline to Month 24

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 24. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 24

  22. Number of Participants With Shift in Tanner Stage From Baseline to Month 36

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 36. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 36

  23. Number of Participants With Shift in Tanner Stage From Baseline to Month 48

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 48. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 48

  24. Number of Participants With Shift in Tanner Stage From Baseline to Month 60

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 60. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 60

  25. Number of Participants With Shift in Tanner Stage From Baseline to Month 72

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 72. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 72

  26. Number of Participants With Shift in Tanner Stage From Baseline to Month 84

    Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 84. Only rows with non-zero values were reported in this outcome measure.

    Time frame: Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 84

Secondary outcomes

  1. Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Systemic Juvenile Idiopathic Arthritis (sJIA) 1 Analysis Set

    Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a visual analogue scale (VAS). Higher scores signified more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  2. Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  3. Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity. In this outcome measure pJIA stands for polyarticular course juvenile idiopathic arthritis.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  4. Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Enthesitis Related Arthritis (ERA) Analysis Set

    Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  5. Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Psoriatic Arthritis (PsA) Analysis Set

    Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  6. Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  7. Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  8. Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  9. Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  10. Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  11. Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  12. Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  13. Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  14. Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  15. Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  16. Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  17. Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  18. Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  19. Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  20. Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  21. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  22. Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  23. Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  24. Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  25. Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  26. Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  27. Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  28. Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  29. Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  30. Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  31. Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  32. Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  33. Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  34. Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  35. Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  36. Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  37. Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  38. Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  39. Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  40. Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  41. Percentage of Participants Achieving a JIA American College of Rheumatology 30 (ACR 30) Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  42. Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  43. Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  44. Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  45. Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  46. Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  47. Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  48. Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  49. Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  50. Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  51. Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  52. Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  53. Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  54. Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  55. Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  56. Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  57. Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  58. Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  59. Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  60. Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  61. Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  62. Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  63. Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  64. Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  65. Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  66. Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree Celsius(C) oral or \>38.6 degree C rectal on \>=2 consecutive days.

    Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  67. Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree C oral or \>38.6 degree C rectal on \>=2 consecutive days.

    Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  68. Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

    Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  69. Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

    Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  70. Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

    Time frame: At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  71. Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  72. Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  73. Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  74. Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  75. Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  76. Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the standardization of uveitis nomenclature \[SUN\] working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

    Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  77. Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

    Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  78. Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

    Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  79. Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

    Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  80. Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

    Time frame: At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  81. Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  82. Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  83. Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  84. Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  85. Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  86. Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  87. Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  88. Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  89. Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  90. Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  91. Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  92. Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  93. Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  94. Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  95. Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  96. Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  97. Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  98. Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1,3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78

  99. Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  100. Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

    JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  101. Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA1 Analysis Set

    Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, methotrexate (MTX)/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

    Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)

  102. Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA2 Analysis Set

    Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

    Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)

  103. Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in pJIA Analysis Set

    Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

    Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)

  104. Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in ERA Analysis Set

    Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

    Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)

  105. Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in PsA Analysis Set

    Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

    Time frame: From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)

  106. Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

    Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  107. Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

    Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.

    Time frame: At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  108. Change From Baseline in Tender Entheseal Assessment at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

    Tender entheseal assessment was performed by the investigator as 'Yes' or 'No'. 'Yes' indicated the presence of tenderness upon firm palpation over the specified enthesis and 'No' indicated the absence of tenderness upon firm palpation over the indicated enthesis. A total of 16 entheseal sites were assessed and the number of tender sites was counted. The score ranges from 0 to 16, where 0 represents the best possible outcome (no tenderness) and 16 represents the worst possible outcome (maximum tenderness).

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

  109. Change From Baseline in Modified Schober's Test at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

    Modified Schober's test was performed at the study visits only in participants with enthesitis-related arthritis. With the participant standing erect and with feet together, a line joining the posterior superior iliac spines (the dimples of Venus) was used as a landmark for the lumbosacral junction. A mark was made 5 centimeters (cm) below and 10 cm above the lumbosacral junction. With the participant in maximum forward flexion with the knees straight, the investigator measures the distance between the two marks in centimeters. The full measurement between the two lines was recorded to the nearest tenth of a centimeter (e.g., 15.2 cm) on the appropriate CRF.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

  110. Change From Baseline in Overall Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

    Severity of overall back pain (at any time) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

  111. Change From Baseline in Nocturnal Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

    Severity of nocturnal back pain (at night) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

  112. Change From Baseline in Body Surface Area (BSA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set

    BSA was measured as the percentage of BSA affected by psoriasis using the palm method; the participants palm was used for the calculation. One of the participant's palm to proximal interphalangeal (PIP) and thumb equals to 1% of BSA. Regions of the body included along with percentage of BSA: 1) head and neck = 10% (10 palms); 2) upper extremities = 20% (20 palms); 3) trunk (axillae and groin) = 30% (30 palms) and 4) lower extremities (buttocks) = 40% (40 palms).Total BSA was sum of all regions ranged from 0% to 100% (100 palms). The physician assessed the total BSA affected by psoriasis using the addition of the individual regions.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

  113. Change From Baseline in Physician's Global Assessment (PGA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set

    PGA was used to determine participant's overall psoriasis lesions at a given time point. Overall lesions were graded for induration, erythema, and scaling based upon scales. Induration scale ranged from: 0 (no evidence of plaque elevation) to 5 (severe plaque elevation or more); erythema scale ranged from: 0 (no evidence of erythema, hyper pigmentation may be present) to 5 (dusky to deep red coloration); scaling scale ranged from: 0 (no evidence of scaling) to 5 (severe; very thick tenacious scale predominates). Total PGA score was calculated based on sum of 3 scales divided by 3 to obtain final PGA, ranging from 0 (no evidence) to 5 (maximum severity); higher scores indicated more severity of psoriasis.

    Time frame: Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36

07

Results

Posted Mar 23, 2026

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BID (Open-label)
Started302
Completed175
Not completed127
Withdrew: Adverse event39
Withdrew: Death1
Withdrew: Lost to follow-up4
Withdrew: Pregnancy2
Withdrew: Protocol violation6
Withdrew: Withdrawal by subject14
Withdrew: Withdrawal by parent/guardian15
Withdrew: Insufficient clinical response35
Withdrew: Other11

Outcome measures

PrimaryNumber of Participants With Laboratory Test Abnormalities

Parameters: Hematology (hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, prothrombin international normalized ratio, erythrocyte sedimentation rate), clinical chemistry (bilirubin, direct/indirect bilirubin, aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high and low density lipoprotein cholesterol, Friedewald estimation, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, C reactive protein), urinalysis (specific gravity, potential of hydrogen (pH), glucose/ protein/ hemoglobin/ erythrocytes/ leukocytes, ketones, leukocyte esterase, hyaline casts, bacteria). Number of participants with at least 1 laboratory abnormality are reported.

Time frame:
During study treatment (maximum up to 118 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsTofacitinib 5 mg BID (Open-label)
Number of Participants With Laboratory Test Abnormalities294
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily had a causal relationship with the treatment or usage. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that met one or more of the following criteria: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. An TEAE was any AE that occurred following the start of study treatment in this study or increased in severity following the start of study treatment in this study. AE included both SAEs and all non-SAEs.

Time frame:
From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTofacitinib 5 mg BID (Open-label)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)268
PrimaryAbsolute Values of Body Weight at Baseline

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
At Baseline
Reported as:
Mean · Kilograms
Absolute Values of Body Weight at Baseline
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute Values of Body Weight at Baseline41.60 ± 19.35
PrimaryAbsolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 12
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 12 and Its Change From Baseline at Month 12
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 1249.16 ± 20.59
Change at Month 126.52 ± 6.71
PrimaryAbsolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 24
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 24 and Its Change From Baseline at Month 24
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 2452.42 ± 20.15
Change at Month 249.42 ± 8.08
PrimaryAbsolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 36
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 36 and Its Change From Baseline at Month 36
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 3656.96 ± 19.96
Change at Month 3612.44 ± 10.34
PrimaryAbsolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 48
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 48 and Its Change From Baseline at Month 48
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 4856.72 ± 17.69
Change at Month 4813.99 ± 11.06
PrimaryAbsolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 60
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 60 and Its Change From Baseline at Month 60
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 6058.07 ± 18.28
Change at Month 6017.50 ± 11.99
PrimaryAbsolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 72
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 72 and Its Change From Baseline at Month 72
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 7258.38 ± 19.40
Change at Month 7220.55 ± 13.49
PrimaryAbsolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84

Body weight was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 84
Reported as:
Mean · Kilograms
Absolute Value of Body Weight at Month 84 and Its Change From Baseline at Month 84
KilogramsTofacitinib 5 mg BID (Open-label)
Absolute at Month 8459.31 ± 18.24
Change at Month 8423.80 ± 12.46
PrimaryAbsolute Value of Height at Baseline

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
At Baseline
Reported as:
Mean · Centimeters
Absolute Value of Height at Baseline
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute Value of Height at Baseline141.36 ± 23.62
PrimaryAbsolute Value of Height at Month 12 and Its Change From Baseline at Month 12

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 12
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 12 and Its Change From Baseline at Month 12
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 12147.87 ± 20.92
Change at Month 125.55 ± 5.66
PrimaryAbsolute Value of Height at Month 24 and Its Change From Baseline at Month 24

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 24
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 24 and Its Change From Baseline at Month 24
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 24151.60 ± 19.34
Change at Month 249.30 ± 7.96
PrimaryAbsolute Value of Height at Month 36 and Its Change From Baseline at Month 36

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 36
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 36 and Its Change From Baseline at Month 36
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 36155.76 ± 16.05
Change at Month 3610.97 ± 10.49
PrimaryAbsolute Value of Height at Month 48 and Its Change From Baseline at Month 48

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 48
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 48 and Its Change From Baseline at Month 48
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 48157.82 ± 14.81
Change at Month 4814.07 ± 12.55
PrimaryAbsolute Value of Height at Month 60 and Its Change From Baseline at Month 60

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 60
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 60 and Its Change From Baseline at Month 60
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 60158.92 ± 14.15
Change at Month 6017.71 ± 14.86
PrimaryAbsolute Value of Height at Month 72 and Its Change From Baseline at Month 72

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 72
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 72 and Its Change From Baseline at Month 72
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 72159.76 ± 14.41
Change at Month 7222.92 ± 16.35
PrimaryAbsolute Value of Height at Month 84 and Its Change From Baseline at Month 84

Height was collected to assess growth and physical development. Baseline value was based on the enrollment gap: either from the qualifying studies (A3921103 \[NCT01513902\], A3921104 \[NCT02592434\], or A3921165 \[NCT03000439\]) (when participants enrolled in the current extension study within 14 days of the last visit of the qualifying/ index study), or from the current extension study (A3921145 \[NCT01500551\]) (when enrollment was out of 14-day window).

Time frame:
Baseline, Month 84
Reported as:
Mean · Centimeters
Absolute Value of Height at Month 84 and Its Change From Baseline at Month 84
CentimetersTofacitinib 5 mg BID (Open-label)
Absolute at Month 84163.15 ± 11.00
Change at Month 8427.95 ± 18.02
PrimaryNumber of Participants According to Tanner Stage at Baseline

Pubertal development was measured using Tanner stage, by age group (2 to \<6 years, 6 to \<12 years, and 12 years or older) for males and females separately. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (fully developed breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes continue to enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size).

Time frame:
At Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap)
Reported as:
Count of participants · Participants
Number of Participants According to Tanner Stage at Baseline
ParticipantsTofacitinib 5 mg BID (Open-label)
Male (2 to <6 Years): Pubic hair stage 112
Male (2 to <6 Years): Genitalia stage 112
Male (6 to <12 Years): Pubic hair stage 126
Male (6 to <12 Years): Genitalia stage 126
Male (6 to <12 Years): Pubic hair stage 23
Male (6 to <12 Years): Genitalia stage 23
Male (12 Years or older): Pubic hair stage 19
Male (12 Years or older): Genitalia stage 16
Male (12 Years or older): Pubic hair stage 26
Male (12 Years or older): Genitalia stage 28
Male (12 Years or older): Pubic hair stage 311
Male (12 Years or older): Genitalia stage 314
Male (12 Years or older): Pubic hair stage 414
Male (12 Years or older): Genitalia stage 413
Male (12 Years or older): Pubic hair stage 59
Male (12 Years or older): Genitalia stage 58
Female (2 to <6 Years): Pubic hair stage 18
Female (2 to <6 Years): Breast exam stage 18
Female (6 to <12 Years): Pubic hair stage 153
Female (6 to <12 Years): Breast exam stage 147
Female (6 to <12 Years): Pubic hair stage 24
Female (6 to <12 Years): Breast exam stage 211
Female (6 to <12 Years): Pubic hair stage 31
Female (12 Years or older): Pubic hair stage 13
Female (12 Years or older): Breast exam stage 11
Female (12 Years or older): Pubic hair stage 214
Female (12 Years or older): Breast exam stage 213
Female (12 Years or older): Pubic hair stage 319
Female (12 Years or older): Breast exam stage 327
Female (12 Years or older): Pubic hair stage 434
Female (12 Years or older): Breast exam stage 434
Female (12 Years or older): Pubic hair stage 544
Female (12 Years or older): Breast exam stage 539
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 12

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 12. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 12
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 12
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12)11
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12)11
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12)18
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12)6
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12)2
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 12)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12)17
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12)5
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12)2
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12)3
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 1 (Month 12)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 12)2
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 12)2
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12)2
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12)2
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12)1
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12)3
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12)4
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12)2
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12)8
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12)5
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12)7
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12)2
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 12)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12)2
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12)4
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 2 (Month 12)1
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12)2
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12)7
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12)2
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12)5
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12)6
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12)6
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12)8
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 12)8
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12)34
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12)11
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12)3
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 12)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 12)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 1 (Month 12)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12)2
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 12)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 12)30
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 12)13
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 12)3
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 1 (Month 12)2
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 12)4
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 12)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 12)2
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 12)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 12)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12)2
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12)5
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12)2
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12)4
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12)6
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12)6
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12)5
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12)1
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12)12
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12)18
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 1 (Month 12)1
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 4 (Month 12)3
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12)35
Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 12)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 12)3
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 12)5
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 12)3
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 12)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 12)4
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 12)12
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 12)9
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 1 (Month 12)1
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 12)1
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 12)9
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 12)20
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 3 (Month 12)1
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 12)33
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 24

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 24. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 24
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 24
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24)7
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24)7
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24)8
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24)3
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24)1
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 24)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24)8
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24)1
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24)1
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 24)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24)3
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 24)2
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 24)1
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24)1
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24)2
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24)2
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24)2
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24)3
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24)4
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 24)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24)2
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24)3
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24)2
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24)2
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24)5
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24)4
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24)8
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 24)8
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24)15
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24)6
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24)4
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 24)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24)2
Female: Pubic hair, 6 to <12 Years- Stage 3 (Baseline) to Stage 5 (Month 24)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 24)13
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 24)7
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 24)5
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 24)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 24)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 24)2
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 24)2
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 2 (Month 24)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 24)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24)3
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24)5
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 24)2
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24)2
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24)8
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 24)1
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24)4
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24)15
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 4 (Month 24)1
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24)24
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 24)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 24)4
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 24)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 3 (Month 24)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 24)5
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 24)12
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 24)6
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 24)16
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 24)21
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 36

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 36. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 36
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 36
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36)3
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36)3
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36)5
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36)1
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36)3
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36)2
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36)1
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 36)3
Male: Pubic Hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36)4
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36)3
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 36)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36)3
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36)1
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36)4
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36)3
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36)7
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 36)7
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36)7
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36)6
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36)4
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 36)4
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 36)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 36)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 36)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 36)8
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 36)5
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 36)5
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 36)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 36)2
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 2 (Month 36)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 3 (Month 36)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 36)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 36)2
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 36)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 36)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 36)2
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36)5
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36)3
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36)8
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 36)1
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36)1
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36)12
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36)24
Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 36)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 36)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 36)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 36)3
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 36)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 36)4
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 36)12
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 36)1
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 36)2
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 36)16
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 36)17
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 48

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 48. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 48
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 48
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48)1
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48)3
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48)2
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48)2
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48)3
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 48)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48)3
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 4 (Month 48)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48)2
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48)3
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 4 (Month 48)1
Male: Genitalia, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48)2
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48)1
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48)2
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48)3
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48)4
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 48)4
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 48)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48)4
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 48)6
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 48)3
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48)2
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 1 (Month 48)3
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 48)5
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 48)3
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 48)5
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 48)2
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 4 (Month 48)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 3 (Month 48)1
Female: Pubic hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 48)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48)3
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48)3
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48)5
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48)8
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48)17
Female: Breast, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 48)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 48)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 4 (Month 48)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 48)2
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 48)3
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 48)8
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 3 (Month 48)1
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 48)8
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 48)14
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 60

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 60. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 60
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 60
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60)1
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60)3
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60)3
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 60)2
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 60)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60)1
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60)2
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 4 (Month 60)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60)1
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60)1
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60)2
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 60)1
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 60)2
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 60)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60)3
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 60)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 60)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60)2
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 2 (Month 60)2
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 60)3
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 60)2
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 60)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 2 (Month 60)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60)1
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 60)6
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60)2
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60)9
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 3 (Month 60)1
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 60)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 60)6
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 60)3
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 60)8
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 72

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 72. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 72
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 72
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72)1
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 72)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72)2
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72)1
Male: Pubic Hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72)2
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72)1
Male: Genitalia, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72)1
Male: Pubic Hair, 12 Years or older- Stage 1 (Baseline) to Stage 5 (Month 72)1
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72)1
Male: Pubic Hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72)1
Male: Genitalia, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72)1
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72)1
Male: Genitalia, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72)1
Female: Pubic hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72)1
Female: Breast, 2 to <6 Years- Stage 1 (Baseline) to Stage 1 (Month 72)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 72)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72)2
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 72)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 72)3
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 72)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 72)1
Female: Pubic hair, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72)1
Female: Pubic hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72)3
Female: Pubic hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72)1
Female: Pubic hair, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72)2
Female: Breast, 12 Years or older- Stage 2 (Baseline) to Stage 5 (Month 72)1
Female: Breast, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 72)3
Female: Breast, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 72)1
Female: Breast, 12 Years or older- Stage 5 (Baseline) to Stage 5 (Month 72)2
PrimaryNumber of Participants With Shift in Tanner Stage From Baseline to Month 84

Pubertal development was measured using Tanner stage, by age group and gender. Assessment included, 1) Male: pubic hair and size of genitalia and 2) Female: pubic hair and breast exam. There were 5 stages for each assessment type. Stages for, a) Pubic hair: 1 (no hair), 2 (downy hair), 3 (scant terminal hair), 4 (terminal hair filled entire triangle overlying pubic region), 5 (terminal hair extended beyond inguinal crease onto thigh); b) Breast exam: 1 (no breast development), 2 (breasts buds), 3 (breast tissue palpable outside areola; no areolar development), 4 (secondary mounds, separation of contours), 5 (full breast); c) Genitalia: 1 (no genital growth), 2 (enlargement of scrotum and testes), 3 (penis grow in size, testes enlarge), 4 (penis grow in length/ breadth, scrotum darkens, testes enlarge), 5 (adult shape and size). Number of participants are reported per shift in Tanner stage from Baseline to Month 84. Only rows with non-zero values were reported in this outcome measure.

Time frame:
Baseline (from the qualifying/ index studies or the current extension study based on the enrollment gap), at Month 84
Reported as:
Count of participants · Participants
Number of Participants With Shift in Tanner Stage From Baseline to Month 84
ParticipantsTofacitinib 5 mg BID (Open-label)
Male: Pubic Hair, 2 to <6 Years- Stage 1 (Baseline) to Stage 3 (Month 84)1
Male: Genitalia, 2 to <6 Years- Stage 1 (Baseline) to Stage 2 (Month 84)1
Male: Pubic Hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84)1
Male: Genitalia, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84)1
Male: Pubic Hair, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 84)1
Male: Pubic Hair, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 84)1
Male: Genitalia, 12 Years or older- Stage 3 (Baseline) to Stage 5 (Month 84)1
Male: Genitalia, 12 Years or older- Stage 4 (Baseline) to Stage 5 (Month 84)1
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 84)2
Female: Pubic hair, 6 to <12 Years- Stage 1 (Baseline) to Stage 5 (Month 84)1
Female: Pubic hair, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 84)1
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 3 (Month 84)2
Female: Breast, 6 to <12 Years- Stage 1 (Baseline) to Stage 4 (Month 84)1
Female: Breast, 6 to <12 Years- Stage 2 (Baseline) to Stage 5 (Month 84)1
SecondaryChange From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Systemic Juvenile Idiopathic Arthritis (sJIA) 1 Analysis Set

Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a visual analogue scale (VAS). Higher scores signified more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Systemic Juvenile Idiopathic Arthritis (sJIA) 1 Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.44 ± 2.70
Change at Month 3-4.95 ± 2.63
Change at Month 6-5.33 ± 2.44
Change at Month 9-5.02 ± 2.59
Change at Month 12-5.13 ± 2.30
Change at Month 15-4.49 ± 2.55
Change at Month 18-4.82 ± 2.81
Change at Month 21-4.84 ± 2.41
Change at Month 24-4.80 ± 2.38
Change at Month 27-5.00 ± 2.45
Change at Month 30-5.59 ± 2.13
Change at Month 33-5.42 ± 2.16
Change at Month 36-5.72 ± 2.39
SecondaryChange From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.56 ± 2.66
Change at Month 3-5.07 ± 2.50
Change at Month 6-5.24 ± 2.48
Change at Month 9-5.01 ± 2.63
Change at Month 12-4.98 ± 2.33
Change at Month 15-4.39 ± 2.54
Change at Month 18-4.83 ± 2.81
Change at Month 21-4.76 ± 2.40
Change at Month 24-4.67 ± 2.36
Change at Month 27-4.74 ± 2.39
Change at Month 30-5.77 ± 2.13
Change at Month 33-5.38 ± 2.46
Change at Month 36-4.90 ± 2.77
SecondaryChange From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity. In this outcome measure pJIA stands for polyarticular course juvenile idiopathic arthritis.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Score on a scale
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.24 ± 2.29
Change at Month 3-4.71 ± 2.14
Change at Month 6-4.79 ± 2.14
Change at Month 9-4.94 ± 2.07
Change at Month 12-4.98 ± 2.22
Change at Month 15-5.20 ± 2.16
Change at Month 18-5.20 ± 2.17
Change at Month 21-5.14 ± 2.26
Change at Month 24-5.27 ± 2.07
Change at Month 27-5.23 ± 2.02
Change at Month 30-5.24 ± 2.05
Change at Month 33-5.40 ± 2.00
Change at Month 36-5.50 ± 2.00
Change at Month 39-5.41 ± 2.19
Change at Month 42-5.59 ± 2.03
Change at Month 45-5.63 ± 1.98
Change at Month 48-5.86 ± 1.82
Change at Month 51-5.77 ± 1.89
Change at Month 54-5.91 ± 1.63
Change at Month 57-5.90 ± 1.78
Change at Month 60-5.82 ± 1.91
Change at Month 63-6.05 ± 1.82
Change at Month 66-5.71 ± 2.04
Change at Month 69-5.91 ± 1.79
Change at Month 72-5.91 ± 1.85
Change at Month 75-5.93 ± 1.84
Change at Month 78-6.23 ± 1.75
SecondaryChange From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Enthesitis Related Arthritis (ERA) Analysis Set

Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Enthesitis Related Arthritis (ERA) Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.00 ± 1.72
Change at Month 3-3.76 ± 1.59
Change at Month 6-3.37 ± 1.80
Change at Month 9-4.13 ± 1.43
Change at Month 12-3.80 ± 1.57
Change at Month 15-3.96 ± 1.66
Change at Month 18-4.33 ± 1.29
Change at Month 21-4.58 ± 1.06
Change at Month 24-4.23 ± 1.72
Change at Month 27-4.13 ± 1.30
Change at Month 30-4.27 ± 1.37
Change at Month 33-4.25 ± 1.36
Change at Month 36-4.17 ± 1.42
SecondaryChange From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Psoriatic Arthritis (PsA) Analysis Set

Physician global evaluation of disease activity assessed overall arthritis appearance at specified time points. The evaluation was based on the participant's disease signs, functional capacity and physical examination. The investigator rated the overall level of disease activity by entering a number from 0 (no disease activity) to 10 (maximum disease activity) on a VAS. Higher scores signified more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Physician Global Evaluation of Disease Activity Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in Psoriatic Arthritis (PsA) Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.18 ± 2.36
Change at Month 3-4.36 ± 2.15
Change at Month 6-4.84 ± 1.89
Change at Month 9-5.00 ± 1.87
Change at Month 12-4.75 ± 1.96
Change at Month 15-4.70 ± 2.09
Change at Month 18-4.69 ± 1.89
Change at Month 21-4.69 ± 2.01
Change at Month 24-4.95 ± 2.45
Change at Month 27-4.96 ± 2.10
Change at Month 30-4.62 ± 2.07
Change at Month 33-4.83 ± 2.07
Change at Month 36-4.39 ± 2.09
SecondaryChange From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Active Arthritis
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Joints With Active ArthritisTofacitinib 5 mg BID (Open-label)
Change at Month 1-7.31 ± 7.40
Change at Month 3-7.65 ± 8.15
Change at Month 6-8.69 ± 7.68
Change at Month 9-8.65 ± 7.48
Change at Month 12-10.15 ± 8.39
Change at Month 15-9.08 ± 7.45
Change at Month 18-9.31 ± 7.43
Change at Month 21-10.45 ± 8.13
Change at Month 24-10.44 ± 8.20
Change at Month 27-10.38 ± 8.45
Change at Month 30-10.47 ± 8.24
Change at Month 33-11.42 ± 8.45
Change at Month 36-11.33 ± 8.60
SecondaryChange From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Active Arthritis
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Joints With Active ArthritisTofacitinib 5 mg BID (Open-label)
Change at Month 1-7.03 ± 7.34
Change at Month 3-7.68 ± 7.82
Change at Month 6-8.28 ± 7.68
Change at Month 9-8.33 ± 7.44
Change at Month 12-9.72 ± 8.50
Change at Month 15-8.53 ± 7.34
Change at Month 18-8.72 ± 7.27
Change at Month 21-9.43 ± 8.08
Change at Month 24-9.67 ± 8.11
Change at Month 27-9.42 ± 8.18
Change at Month 30-9.38 ± 8.24
Change at Month 33-9.88 ± 8.31
Change at Month 36-7.60 ± 7.57
SecondaryChange From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Joints With Active Arthritis
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Joints With Active ArthritisTofacitinib 5 mg BID (Open-label)
Change at Month 1-9.64 ± 7.24
Change at Month 3-10.36 ± 7.56
Change at Month 6-10.44 ± 6.91
Change at Month 9-10.45 ± 7.00
Change at Month 12-10.98 ± 7.10
Change at Month 15-10.87 ± 6.54
Change at Month 18-11.19 ± 7.67
Change at Month 21-11.39 ± 7.35
Change at Month 24-11.31 ± 6.83
Change at Month 27-11.22 ± 6.70
Change at Month 30-11.25 ± 7.40
Change at Month 33-11.72 ± 7.35
Change at Month 36-11.57 ± 7.54
Change at Month 39-11.36 ± 7.21
Change at Month 42-11.25 ± 7.14
Change at Month 45-11.24 ± 7.76
Change at Month 48-11.38 ± 7.04
Change at Month 51-11.03 ± 7.18
Change at Month 54-10.92 ± 5.98
Change at Month 57-10.55 ± 6.00
Change at Month 60-9.96 ± 5.14
Change at Month 63-10.35 ± 6.28
Change at Month 66-9.95 ± 5.46
Change at Month 69-10.68 ± 6.02
Change at Month 72-10.49 ± 6.06
Change at Month 75-10.50 ± 6.03
Change at Month 78-10.30 ± 5.74
SecondaryChange From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Active Arthritis
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Joints With Active ArthritisTofacitinib 5 mg BID (Open-label)
Change at Month 1-6.71 ± 3.85
Change at Month 3-6.24 ± 3.13
Change at Month 6-6.16 ± 3.53
Change at Month 9-6.87 ± 2.97
Change at Month 12-7.07 ± 3.37
Change at Month 15-7.54 ± 2.57
Change at Month 18-7.67 ± 3.39
Change at Month 21-7.75 ± 3.25
Change at Month 24-6.82 ± 4.62
Change at Month 27-7.25 ± 3.39
Change at Month 30-7.45 ± 2.91
Change at Month 33-7.33 ± 3.73
Change at Month 36-7.17 ± 3.71
SecondaryChange From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

Active arthritis was defined as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion, or tenderness not due to deformity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Active Arthritis
Change From Baseline in Number of Joints With Active Arthritis at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Joints With Active ArthritisTofacitinib 5 mg BID (Open-label)
Change at Month 1-8.68 ± 6.82
Change at Month 3-9.28 ± 6.23
Change at Month 6-9.94 ± 6.51
Change at Month 9-10.00 ± 6.49
Change at Month 12-9.75 ± 6.75
Change at Month 15-9.93 ± 7.12
Change at Month 18-10.54 ± 7.53
Change at Month 21-10.92 ± 7.16
Change at Month 24-10.73 ± 6.00
Change at Month 27-11.33 ± 7.54
Change at Month 30-10.54 ± 7.83
Change at Month 33-10.92 ± 7.84
Change at Month 36-9.11 ± 8.13
SecondaryChange From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Limitation of Motion
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Joints With Limitation of MotionTofacitinib 5 mg BID (Open-label)
Change at Month 1-3.60 ± 5.69
Change at Month 3-3.85 ± 5.61
Change at Month 6-4.21 ± 6.47
Change at Month 9-4.40 ± 5.80
Change at Month 12-5.02 ± 6.04
Change at Month 15-5.50 ± 7.06
Change at Month 18-5.08 ± 6.31
Change at Month 21-5.38 ± 7.08
Change at Month 24-5.67 ± 7.04
Change at Month 27-5.75 ± 7.50
Change at Month 30-4.53 ± 6.78
Change at Month 33-3.67 ± 5.73
Change at Month 36-4.67 ± 6.18
SecondaryChange From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Limitation of Motion
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Joints With Limitation of MotionTofacitinib 5 mg BID (Open-label)
Change at Month 1-3.26 ± 5.45
Change at Month 3-3.50 ± 5.47
Change at Month 6-3.65 ± 5.99
Change at Month 9-3.99 ± 5.65
Change at Month 12-4.68 ± 5.93
Change at Month 15-4.78 ± 6.66
Change at Month 18-4.44 ± 6.02
Change at Month 21-4.52 ± 7.06
Change at Month 24-4.81 ± 7.05
Change at Month 27-5.16 ± 7.44
Change at Month 30-3.54 ± 6.53
Change at Month 33-1.63 ± 3.58
Change at Month 36-1.20 ± 2.17
SecondaryChange From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Joints With Limitation of Motion
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Joints With Limitation of MotionTofacitinib 5 mg BID (Open-label)
Change at Month 1-5.48 ± 5.99
Change at Month 3-5.97 ± 5.96
Change at Month 6-6.13 ± 6.41
Change at Month 9-6.25 ± 6.38
Change at Month 12-6.22 ± 6.29
Change at Month 15-6.72 ± 6.76
Change at Month 18-6.61 ± 6.61
Change at Month 21-6.59 ± 6.59
Change at Month 24-6.71 ± 6.22
Change at Month 27-6.59 ± 6.18
Change at Month 30-6.71 ± 7.13
Change at Month 33-6.69 ± 6.63
Change at Month 36-7.09 ± 6.72
Change at Month 39-7.13 ± 6.72
Change at Month 42-6.80 ± 6.67
Change at Month 45-7.13 ± 6.38
Change at Month 48-7.20 ± 6.16
Change at Month 51-7.42 ± 7.05
Change at Month 54-6.69 ± 5.37
Change at Month 57-6.53 ± 6.21
Change at Month 60-6.31 ± 5.13
Change at Month 63-6.70 ± 6.54
Change at Month 66-6.33 ± 5.42
Change at Month 69-7.00 ± 6.51
Change at Month 72-7.16 ± 6.68
Change at Month 75-7.20 ± 6.47
Change at Month 78-7.21 ± 5.58
SecondaryChange From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Limitation of Motion
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Joints With Limitation of MotionTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.48 ± 3.44
Change at Month 3-4.29 ± 4.48
Change at Month 6-4.00 ± 5.66
Change at Month 9-5.13 ± 4.70
Change at Month 12-5.53 ± 5.00
Change at Month 15-6.08 ± 5.38
Change at Month 18-5.50 ± 5.18
Change at Month 21-5.42 ± 4.98
Change at Month 24-4.82 ± 6.00
Change at Month 27-5.08 ± 5.02
Change at Month 30-5.55 ± 5.13
Change at Month 33-4.58 ± 2.87
Change at Month 36-4.58 ± 4.01
SecondaryChange From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Joints With Limitation of Motion
Change From Baseline in Number of Joints With Limitation of Motion at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Joints With Limitation of MotionTofacitinib 5 mg BID (Open-label)
Change at Month 1-5.00 ± 4.83
Change at Month 3-5.06 ± 4.82
Change at Month 6-5.63 ± 5.11
Change at Month 9-5.50 ± 4.77
Change at Month 12-4.88 ± 4.41
Change at Month 15-5.07 ± 4.85
Change at Month 18-4.85 ± 5.34
Change at Month 21-5.00 ± 5.24
Change at Month 24-5.27 ± 4.36
Change at Month 27-5.50 ± 5.30
Change at Month 30-5.31 ± 5.51
Change at Month 33-5.42 ± 5.95
Change at Month 36-3.78 ± 5.47
SecondaryChange From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
milligrams per deciliter (mg/dL)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-2.29 ± 4.58
Change at Month 3-2.43 ± 4.63
Change at Month 6-2.67 ± 4.16
Change at Month 9-2.22 ± 4.47
Change at Month 12-2.25 ± 5.43
Change at Month 15-2.50 ± 4.02
Change at Month 18-2.09 ± 4.34
Change at Month 21-3.01 ± 3.49
Change at Month 24-2.71 ± 3.26
Change at Month 27-1.78 ± 4.23
Change at Month 30-2.46 ± 3.58
Change at Month 33-1.57 ± 1.80
Change at Month 36-0.88 ± 1.50
SecondaryChange From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
milligrams per deciliter (mg/dL)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-2.50 ± 4.86
Change at Month 3-2.76 ± 4.81
Change at Month 6-2.84 ± 4.32
Change at Month 9-2.33 ± 4.68
Change at Month 12-2.34 ± 5.75
Change at Month 15-2.87 ± 4.23
Change at Month 18-2.47 ± 4.56
Change at Month 21-3.44 ± 3.77
Change at Month 24-3.13 ± 3.55
Change at Month 27-2.24 ± 4.56
Change at Month 30-3.01 ± 3.80
Change at Month 33-1.64 ± 1.99
Change at Month 36-0.70 ± 1.42
SecondaryChange From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
milligrams per deciliter (mg/dL)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-0.78 ± 1.97
Change at Month 3-0.71 ± 2.08
Change at Month 6-0.79 ± 2.07
Change at Month 9-0.77 ± 2.17
Change at Month 12-0.71 ± 2.01
Change at Month 15-0.71 ± 2.41
Change at Month 18-0.65 ± 2.16
Change at Month 21-0.77 ± 2.17
Change at Month 24-0.91 ± 2.16
Change at Month 27-0.46 ± 3.78
Change at Month 30-0.86 ± 2.18
Change at Month 33-0.90 ± 2.21
Change at Month 36-0.85 ± 2.21
Change at Month 39-0.86 ± 2.27
Change at Month 42-0.92 ± 2.21
Change at Month 45-0.83 ± 2.17
Change at Month 48-1.04 ± 2.49
Change at Month 51-0.96 ± 2.52
Change at Month 54-0.81 ± 2.83
Change at Month 57-0.93 ± 2.61
Change at Month 60-0.57 ± 1.20
Change at Month 63-0.60 ± 1.96
Change at Month 66-0.35 ± 2.55
Change at Month 69-0.69 ± 1.80
Change at Month 72-0.30 ± 3.05
Change at Month 75-0.29 ± 1.70
Change at Month 78-0.70 ± 1.14
SecondaryChange From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
milligrams per deciliter (mg/dL)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-0.09 ± 0.88
Change at Month 3-0.07 ± 0.84
Change at Month 6-0.09 ± 0.85
Change at Month 90.01 ± 0.65
Change at Month 120.19 ± 0.90
Change at Month 150.08 ± 0.51
Change at Month 18-0.05 ± 0.33
Change at Month 21-0.08 ± 0.25
Change at Month 240.06 ± 0.35
Change at Month 27-0.04 ± 0.35
Change at Month 30-0.09 ± 0.21
Change at Month 33-0.07 ± 0.24
Change at Month 36-0.05 ± 0.19
SecondaryChange From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

CRP was a laboratory measurement test for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
milligrams per deciliter (mg/dL)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-0.37 ± 1.50
Change at Month 3-0.63 ± 1.58
Change at Month 6-0.66 ± 1.54
Change at Month 9-0.64 ± 1.49
Change at Month 12-0.64 ± 1.50
Change at Month 15-0.32 ± 1.81
Change at Month 180.79 ± 5.73
Change at Month 21-0.62 ± 1.54
Change at Month 24-0.61 ± 1.51
Change at Month 27-0.36 ± 2.14
Change at Month 30-0.51 ± 0.96
Change at Month 33-0.63 ± 1.82
Change at Month 36-0.92 ± 1.74
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · millimeters per hour (mm/hr)
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
millimeters per hour (mm/hr)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-28.69 ± 29.50
Change at Month 3-32.32 ± 30.44
Change at Month 6-34.61 ± 27.26
Change at Month 9-29.47 ± 30.87
Change at Month 12-27.54 ± 35.19
Change at Month 15-25.53 ± 35.89
Change at Month 18-23.63 ± 34.29
Change at Month 21-27.10 ± 29.10
Change at Month 24-29.07 ± 30.61
Change at Month 27-20.25 ± 27.77
Change at Month 30-21.88 ± 26.15
Change at Month 33-14.33 ± 22.44
Change at Month 36-8.89 ± 19.80
SecondaryChange From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · millimeters per hour (mm/hr)
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
millimeters per hour (mm/hr)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-30.49 ± 29.84
Change at Month 3-34.05 ± 30.25
Change at Month 6-36.21 ± 26.24
Change at Month 9-30.55 ± 30.45
Change at Month 12-29.17 ± 33.37
Change at Month 15-26.74 ± 36.37
Change at Month 18-25.55 ± 35.04
Change at Month 21-29.00 ± 27.65
Change at Month 24-30.38 ± 29.67
Change at Month 27-20.42 ± 26.62
Change at Month 30-27.31 ± 25.43
Change at Month 33-22.25 ± 18.71
Change at Month 36-8.80 ± 26.41
SecondaryChange From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · millimeters per hour (mm/hr)
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
millimeters per hour (mm/hr)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-10.48 ± 21.15
Change at Month 3-10.52 ± 24.64
Change at Month 6-10.01 ± 23.81
Change at Month 9-11.31 ± 23.06
Change at Month 12-8.75 ± 23.64
Change at Month 15-11.53 ± 23.75
Change at Month 18-10.09 ± 23.56
Change at Month 21-10.80 ± 23.95
Change at Month 24-10.87 ± 25.27
Change at Month 27-9.96 ± 24.00
Change at Month 30-8.82 ± 24.92
Change at Month 33-9.69 ± 22.09
Change at Month 36-8.13 ± 22.82
Change at Month 39-7.54 ± 22.93
Change at Month 42-8.74 ± 22.91
Change at Month 45-8.78 ± 20.76
Change at Month 48-9.15 ± 24.99
Change at Month 51-8.83 ± 22.74
Change at Month 54-10.05 ± 24.80
Change at Month 57-7.87 ± 24.53
Change at Month 60-3.13 ± 24.64
Change at Month 63-5.30 ± 22.11
Change at Month 66-4.16 ± 22.98
Change at Month 69-7.22 ± 18.11
Change at Month 72-7.77 ± 18.49
Change at Month 75-4.04 ± 24.52
Change at Month 78-8.87 ± 18.67
SecondaryChange From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · millimeters per hour (mm/hr)
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
millimeters per hour (mm/hr)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-5.74 ± 22.70
Change at Month 3-6.84 ± 22.73
Change at Month 6-5.89 ± 23.81
Change at Month 9-3.53 ± 13.69
Change at Month 12-0.87 ± 16.34
Change at Month 15-3.31 ± 18.30
Change at Month 18-8.42 ± 15.37
Change at Month 21-7.42 ± 15.49
Change at Month 24-3.92 ± 15.96
Change at Month 27-2.64 ± 29.16
Change at Month 30-7.55 ± 13.52
Change at Month 33-5.75 ± 13.84
Change at Month 36-6.00 ± 12.65
SecondaryChange From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

ESR was a laboratory test that provides a measure of inflammation. A higher rate is consistent with inflammation.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · millimeters per hour (mm/hr)
Change From Baseline in ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
millimeters per hour (mm/hr)Tofacitinib 5 mg BID (Open-label)
Change at Month 1-10.00 ± 21.55
Change at Month 3-9.33 ± 27.47
Change at Month 6-12.27 ± 23.62
Change at Month 9-12.60 ± 24.47
Change at Month 12-12.13 ± 22.19
Change at Month 15-8.67 ± 23.58
Change at Month 18-7.36 ± 27.03
Change at Month 21-10.67 ± 21.12
Change at Month 24-6.82 ± 15.91
Change at Month 27-7.33 ± 16.91
Change at Month 30-4.31 ± 23.33
Change at Month 33-10.36 ± 27.93
Change at Month 36-8.00 ± 25.22
SecondaryChange From Baseline in Childhood Health Assessment Questionnaire (CHAQ) - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-0.87 ± 0.75
Change at Month 3-0.90 ± 0.72
Change at Month 6-0.96 ± 0.71
Change at Month 9-1.00 ± 0.71
Change at Month 12-0.83 ± 0.69
Change at Month 15-0.86 ± 0.70
Change at Month 18-0.81 ± 0.66
Change at Month 21-0.98 ± 0.66
Change at Month 24-1.04 ± 0.66
Change at Month 27-1.04 ± 0.74
Change at Month 30-1.13 ± 0.81
Change at Month 33-1.00 ± 0.92
Change at Month 36-1.07 ± 0.73
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-0.89 ± 0.77
Change at Month 3-0.94 ± 0.73
Change at Month 6-0.96 ± 0.72
Change at Month 9-1.01 ± 0.71
Change at Month 12-0.85 ± 0.67
Change at Month 15-0.85 ± 0.68
Change at Month 18-0.83 ± 0.59
Change at Month 21-0.98 ± 0.64
Change at Month 24-1.07 ± 0.65
Change at Month 27-1.03 ± 0.71
Change at Month 30-1.12 ± 0.76
Change at Month 33-0.89 ± 0.89
Change at Month 36-0.95 ± 0.66
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-0.52 ± 0.51
Change at Month 3-0.52 ± 0.54
Change at Month 6-0.59 ± 0.57
Change at Month 9-0.63 ± 0.61
Change at Month 12-0.65 ± 0.62
Change at Month 15-0.71 ± 0.63
Change at Month 18-0.70 ± 0.65
Change at Month 21-0.72 ± 0.65
Change at Month 24-0.73 ± 0.66
Change at Month 27-0.73 ± 0.68
Change at Month 30-0.71 ± 0.64
Change at Month 33-0.74 ± 0.73
Change at Month 36-0.75 ± 0.72
Change at Month 39-0.75 ± 0.73
Change at Month 42-0.75 ± 0.74
Change at Month 45-0.74 ± 0.73
Change at Month 48-0.80 ± 0.72
Change at Month 51-0.78 ± 0.70
Change at Month 54-0.74 ± 0.67
Change at Month 57-0.78 ± 0.76
Change at Month 60-0.79 ± 0.74
Change at Month 63-0.77 ± 0.74
Change at Month 66-0.79 ± 0.73
Change at Month 69-0.82 ± 0.76
Change at Month 72-0.81 ± 0.74
Change at Month 75-0.80 ± 0.79
Change at Month 78-0.89 ± 0.80
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-0.38 ± 0.45
Change at Month 3-0.31 ± 0.43
Change at Month 6-0.34 ± 0.42
Change at Month 9-0.40 ± 0.40
Change at Month 12-0.39 ± 0.41
Change at Month 15-0.38 ± 0.42
Change at Month 18-0.41 ± 0.35
Change at Month 21-0.48 ± 0.35
Change at Month 24-0.41 ± 0.35
Change at Month 27-0.40 ± 0.47
Change at Month 30-0.36 ± 0.45
Change at Month 33-0.34 ± 0.52
Change at Month 36-0.36 ± 0.56
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. Disability index assessed function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed among a total of 30 items. Each question was rated from Grade 0 to 3, 0= without any difficulty, 1= with some difficulty, 2= with much difficulty, 3= unable to do. If aids or devices were used or assistance was required, the minimum score for that functional area was 2. Parent/legal guardians were required to answer all questions. The disability index was calculated as the mean of the 8 functional areas and scores were averaged to calculate CHAQ disability index, which ranged from 0= no/minimal physical dysfunction to 3= very severe physical dysfunction; higher score indicated more disability.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Physical Function (Disability Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-0.48 ± 0.49
Change at Month 3-0.44 ± 0.49
Change at Month 6-0.44 ± 0.48
Change at Month 9-0.37 ± 0.54
Change at Month 12-0.41 ± 0.44
Change at Month 15-0.37 ± 0.52
Change at Month 18-0.34 ± 0.65
Change at Month 21-0.46 ± 0.63
Change at Month 24-0.42 ± 0.74
Change at Month 27-0.44 ± 0.65
Change at Month 30-0.41 ± 0.60
Change at Month 33-0.49 ± 0.60
Change at Month 36-0.67 ± 0.55
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.54 ± 3.19
Change at Month 3-4.94 ± 2.92
Change at Month 6-5.16 ± 2.85
Change at Month 9-5.23 ± 2.69
Change at Month 12-4.93 ± 2.81
Change at Month 15-4.59 ± 2.91
Change at Month 18-4.47 ± 3.18
Change at Month 21-4.97 ± 2.92
Change at Month 24-4.76 ± 3.01
Change at Month 27-5.06 ± 3.12
Change at Month 30-5.59 ± 3.33
Change at Month 33-4.63 ± 3.23
Change at Month 36-4.50 ± 3.72
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.70 ± 3.14
Change at Month 3-5.19 ± 2.79
Change at Month 6-5.26 ± 2.79
Change at Month 9-5.33 ± 2.55
Change at Month 12-5.06 ± 2.65
Change at Month 15-4.89 ± 2.60
Change at Month 18-4.78 ± 3.05
Change at Month 21-5.35 ± 2.73
Change at Month 24-5.12 ± 2.92
Change at Month 27-5.26 ± 2.97
Change at Month 30-6.00 ± 3.03
Change at Month 33-4.75 ± 3.06
Change at Month 36-4.90 ± 3.65
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-3.16 ± 2.75
Change at Month 3-3.28 ± 2.72
Change at Month 6-3.60 ± 2.66
Change at Month 9-3.66 ± 2.68
Change at Month 12-3.74 ± 2.73
Change at Month 15-3.76 ± 2.62
Change at Month 18-3.89 ± 2.65
Change at Month 21-3.77 ± 2.65
Change at Month 24-3.75 ± 2.82
Change at Month 27-3.99 ± 2.63
Change at Month 30-3.83 ± 2.74
Change at Month 33-3.81 ± 2.78
Change at Month 36-3.86 ± 2.82
Change at Month 39-3.71 ± 2.93
Change at Month 42-3.74 ± 2.76
Change at Month 45-3.88 ± 2.66
Change at Month 48-4.08 ± 2.63
Change at Month 51-4.15 ± 2.58
Change at Month 54-4.16 ± 2.52
Change at Month 57-4.04 ± 2.75
Change at Month 60-3.94 ± 3.03
Change at Month 63-4.37 ± 2.82
Change at Month 66-4.24 ± 2.87
Change at Month 69-4.34 ± 2.85
Change at Month 72-4.21 ± 2.95
Change at Month 75-4.28 ± 2.96
Change at Month 78-4.21 ± 3.09
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-3.32 ± 2.61
Change at Month 3-2.50 ± 3.03
Change at Month 6-3.25 ± 1.99
Change at Month 9-3.00 ± 3.13
Change at Month 12-3.77 ± 1.86
Change at Month 15-2.50 ± 3.07
Change at Month 18-3.71 ± 1.83
Change at Month 21-3.75 ± 1.76
Change at Month 24-3.63 ± 1.86
Change at Month 27-3.36 ± 2.23
Change at Month 30-3.45 ± 2.35
Change at Month 33-3.91 ± 1.92
Change at Month 36-3.63 ± 2.01
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For the assessment of discomfort index, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall arthritis pain of participant from 0 (no pain) to 10 (very severe pain), on a VAS, where higher scores indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Child's Arthritis Pain (Discomfort Index) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.07 ± 2.67
Change at Month 3-4.34 ± 2.48
Change at Month 6-4.77 ± 2.69
Change at Month 9-3.60 ± 2.69
Change at Month 12-4.70 ± 2.84
Change at Month 15-3.90 ± 2.63
Change at Month 18-3.73 ± 3.49
Change at Month 21-3.92 ± 3.02
Change at Month 24-4.42 ± 2.58
Change at Month 27-3.79 ± 4.06
Change at Month 30-4.25 ± 2.73
Change at Month 33-3.91 ± 3.27
Change at Month 36-4.67 ± 3.08
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.53 ± 3.08
Change at Month 3-5.04 ± 2.66
Change at Month 6-5.11 ± 2.98
Change at Month 9-5.38 ± 2.62
Change at Month 12-4.85 ± 2.91
Change at Month 15-4.44 ± 3.01
Change at Month 18-4.40 ± 3.36
Change at Month 21-4.86 ± 3.03
Change at Month 24-4.57 ± 3.23
Change at Month 27-4.96 ± 3.28
Change at Month 30-5.56 ± 3.45
Change at Month 33-4.42 ± 3.45
Change at Month 36-4.11 ± 3.74
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-4.71 ± 3.06
Change at Month 3-5.32 ± 2.51
Change at Month 6-5.25 ± 2.95
Change at Month 9-5.51 ± 2.53
Change at Month 12-5.12 ± 2.71
Change at Month 15-4.83 ± 2.85
Change at Month 18-4.94 ± 3.09
Change at Month 21-5.48 ± 2.64
Change at Month 24-5.24 ± 2.89
Change at Month 27-5.58 ± 2.93
Change at Month 30-6.38 ± 2.72
Change at Month 33-5.25 ± 2.90
Change at Month 36-5.50 ± 3.41
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-2.83 ± 2.51
Change at Month 3-3.01 ± 2.62
Change at Month 6-3.34 ± 2.51
Change at Month 9-3.36 ± 2.59
Change at Month 12-3.38 ± 2.77
Change at Month 15-3.47 ± 2.43
Change at Month 18-3.54 ± 2.74
Change at Month 21-3.46 ± 2.75
Change at Month 24-3.51 ± 2.84
Change at Month 27-3.73 ± 2.65
Change at Month 30-3.56 ± 2.86
Change at Month 33-3.52 ± 2.58
Change at Month 36-3.62 ± 2.81
Change at Month 39-3.43 ± 2.83
Change at Month 42-3.57 ± 2.72
Change at Month 45-3.57 ± 2.77
Change at Month 48-3.84 ± 2.63
Change at Month 51-3.78 ± 2.69
Change at Month 54-4.02 ± 2.73
Change at Month 57-3.92 ± 2.91
Change at Month 60-3.82 ± 3.11
Change at Month 63-4.22 ± 3.02
Change at Month 66-3.88 ± 2.83
Change at Month 69-3.98 ± 2.89
Change at Month 72-3.80 ± 3.08
Change at Month 75-3.87 ± 3.02
Change at Month 78-3.88 ± 3.11
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-1.32 ± 2.59
Change at Month 3-1.69 ± 2.04
Change at Month 6-2.03 ± 1.88
Change at Month 9-2.93 ± 1.80
Change at Month 12-2.27 ± 1.93
Change at Month 15-2.62 ± 1.56
Change at Month 18-2.75 ± 1.47
Change at Month 21-2.83 ± 1.57
Change at Month 24-2.71 ± 2.10
Change at Month 27-2.68 ± 1.72
Change at Month 30-2.20 ± 2.29
Change at Month 33-2.50 ± 1.43
Change at Month 36-2.79 ± 1.62
SecondaryChange From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

CHAQ comprised of: disability index and discomfort index, and parent global assessment of overall well-being. For assessment of parent global assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being from 0 (very well) to 10 (very poor) on a VAS, where higher score indicated poor well-being.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in CHAQ - Parental Evaluation of Overall Well-being at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-2.96 ± 3.01
Change at Month 3-3.03 ± 3.01
Change at Month 6-3.43 ± 2.85
Change at Month 9-2.60 ± 2.68
Change at Month 12-3.17 ± 3.54
Change at Month 15-2.53 ± 3.32
Change at Month 18-3.00 ± 3.43
Change at Month 21-2.75 ± 3.31
Change at Month 24-3.42 ± 3.21
Change at Month 27-3.54 ± 3.58
Change at Month 30-3.75 ± 3.33
Change at Month 33-3.41 ± 3.53
Change at Month 36-3.89 ± 3.37
SecondaryPercentage of Participants Achieving a JIA American College of Rheumatology 30 (ACR 30) Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA American College of Rheumatology 30 (ACR 30) Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 30 at Month 184.71
JIA ACR 30 at Month 386.59
JIA ACR 30 at Month 692.31
JIA ACR 30 at Month 994.74
JIA ACR 30 at Month 1294.92
JIA ACR 30 at Month 1585.42
JIA ACR 30 at Month 1884.62
JIA ACR 30 at Month 2193.10
JIA ACR 30 at Month 2488.89
JIA ACR 30 at Month 2791.67
JIA ACR 30 at Month 3094.12
JIA ACR 30 at Month 3391.67
JIA ACR 30 at Month 36100.00
SecondaryPercentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 30 at Month 184.42
JIA ACR 30 at Month 387.84
JIA ACR 30 at Month 691.67
JIA ACR 30 at Month 994.20
JIA ACR 30 at Month 1296.15
JIA ACR 30 at Month 1585.00
JIA ACR 30 at Month 1887.50
JIA ACR 30 at Month 2195.65
JIA ACR 30 at Month 2495.24
JIA ACR 30 at Month 2794.74
JIA ACR 30 at Month 30100.00
JIA ACR 30 at Month 3387.50
JIA ACR 30 at Month 36100.00
SecondaryPercentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 30 at Month 189.84
JIA ACR 30 at Month 389.05
JIA ACR 30 at Month 692.91
JIA ACR 30 at Month 992.25
JIA ACR 30 at Month 1292.86
JIA ACR 30 at Month 1595.59
JIA ACR 30 at Month 1889.60
JIA ACR 30 at Month 2193.44
JIA ACR 30 at Month 2492.79
JIA ACR 30 at Month 2797.27
JIA ACR 30 at Month 3092.59
JIA ACR 30 at Month 3396.40
JIA ACR 30 at Month 3696.33
JIA ACR 30 at Month 3994.29
JIA ACR 30 at Month 4295.05
JIA ACR 30 at Month 4594.51
JIA ACR 30 at Month 4897.50
JIA ACR 30 at Month 5194.03
JIA ACR 30 at Month 5498.18
JIA ACR 30 at Month 5794.34
JIA ACR 30 at Month 6093.48
JIA ACR 30 at Month 6390.24
JIA ACR 30 at Month 6687.18
JIA ACR 30 at Month 6992.50
JIA ACR 30 at Month 7289.74
JIA ACR 30 at Month 7594.29
JIA ACR 30 at Month 7889.29
SecondaryPercentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 30 at Month 190.91
JIA ACR 30 at Month 385.71
JIA ACR 30 at Month 687.50
JIA ACR 30 at Month 992.31
JIA ACR 30 at Month 1286.67
JIA ACR 30 at Month 1592.31
JIA ACR 30 at Month 18100.00
JIA ACR 30 at Month 21100.00
JIA ACR 30 at Month 2490.91
JIA ACR 30 at Month 27100.00
JIA ACR 30 at Month 3090.91
JIA ACR 30 at Month 33100.00
JIA ACR 30 at Month 3683.33
SecondaryPercentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR 30 response was defined as follows: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 30 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 30 at Month 186.67
JIA ACR 30 at Month 393.33
JIA ACR 30 at Month 6100.00
JIA ACR 30 at Month 993.33
JIA ACR 30 at Month 1293.33
JIA ACR 30 at Month 1580.00
JIA ACR 30 at Month 1876.92
JIA ACR 30 at Month 2191.67
JIA ACR 30 at Month 2490.91
JIA ACR 30 at Month 2775.00
JIA ACR 30 at Month 3083.33
JIA ACR 30 at Month 3372.73
JIA ACR 30 at Month 36100.00
SecondaryPercentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 50 at Month 175.58
JIA ACR 50 at Month 382.93
JIA ACR 50 at Month 691.03
JIA ACR 50 at Month 986.84
JIA ACR 50 at Month 1289.83
JIA ACR 50 at Month 1583.33
JIA ACR 50 at Month 1876.92
JIA ACR 50 at Month 2189.66
JIA ACR 50 at Month 2488.89
JIA ACR 50 at Month 2787.50
JIA ACR 50 at Month 3094.12
JIA ACR 50 at Month 3383.33
JIA ACR 50 at Month 36100.00
SecondaryPercentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 50 at Month 177.92
JIA ACR 50 at Month 385.14
JIA ACR 50 at Month 690.28
JIA ACR 50 at Month 988.41
JIA ACR 50 at Month 1292.31
JIA ACR 50 at Month 1585.00
JIA ACR 50 at Month 1884.38
JIA ACR 50 at Month 2195.65
JIA ACR 50 at Month 2495.24
JIA ACR 50 at Month 2789.47
JIA ACR 50 at Month 30100.00
JIA ACR 50 at Month 3387.50
JIA ACR 50 at Month 36100.00
SecondaryPercentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 50 at Month 179.84
JIA ACR 50 at Month 383.94
JIA ACR 50 at Month 687.23
JIA ACR 50 at Month 987.32
JIA ACR 50 at Month 1287.86
JIA ACR 50 at Month 1590.44
JIA ACR 50 at Month 1886.40
JIA ACR 50 at Month 2187.70
JIA ACR 50 at Month 2490.99
JIA ACR 50 at Month 2792.73
JIA ACR 50 at Month 3092.59
JIA ACR 50 at Month 3392.79
JIA ACR 50 at Month 3693.58
JIA ACR 50 at Month 3990.48
JIA ACR 50 at Month 4292.08
JIA ACR 50 at Month 4593.41
JIA ACR 50 at Month 4893.75
JIA ACR 50 at Month 5192.54
JIA ACR 50 at Month 5496.36
JIA ACR 50 at Month 5794.34
JIA ACR 50 at Month 6091.30
JIA ACR 50 at Month 6390.24
JIA ACR 50 at Month 6687.18
JIA ACR 50 at Month 6992.50
JIA ACR 50 at Month 7289.74
JIA ACR 50 at Month 7591.43
JIA ACR 50 at Month 7889.29
SecondaryPercentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 50 at Month 172.73
JIA ACR 50 at Month 385.71
JIA ACR 50 at Month 687.50
JIA ACR 50 at Month 992.31
JIA ACR 50 at Month 1280.00
JIA ACR 50 at Month 1584.62
JIA ACR 50 at Month 18100.00
JIA ACR 50 at Month 21100.00
JIA ACR 50 at Month 2490.91
JIA ACR 50 at Month 27100.00
JIA ACR 50 at Month 3090.91
JIA ACR 50 at Month 33100.00
JIA ACR 50 at Month 3683.33
SecondaryPercentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR 50 response was defined as follows: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 50 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 50 at Month 180.00
JIA ACR 50 at Month 386.67
JIA ACR 50 at Month 6100.00
JIA ACR 50 at Month 993.33
JIA ACR 50 at Month 1286.67
JIA ACR 50 at Month 1580.00
JIA ACR 50 at Month 1876.92
JIA ACR 50 at Month 2183.33
JIA ACR 50 at Month 2490.91
JIA ACR 50 at Month 2775.00
JIA ACR 50 at Month 3066.67
JIA ACR 50 at Month 3363.64
JIA ACR 50 at Month 3687.50
SecondaryPercentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 70 at Month 163.95
JIA ACR 70 at Month 371.95
JIA ACR 70 at Month 678.21
JIA ACR 70 at Month 976.32
JIA ACR 70 at Month 1276.27
JIA ACR 70 at Month 1568.75
JIA ACR 70 at Month 1869.23
JIA ACR 70 at Month 2172.41
JIA ACR 70 at Month 2477.78
JIA ACR 70 at Month 2775.00
JIA ACR 70 at Month 3076.47
JIA ACR 70 at Month 3383.33
JIA ACR 70 at Month 3688.89
SecondaryPercentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 70 at Month 166.23
JIA ACR 70 at Month 374.32
JIA ACR 70 at Month 679.17
JIA ACR 70 at Month 976.81
JIA ACR 70 at Month 1276.92
JIA ACR 70 at Month 1572.50
JIA ACR 70 at Month 1875.00
JIA ACR 70 at Month 2178.26
JIA ACR 70 at Month 2480.95
JIA ACR 70 at Month 2778.95
JIA ACR 70 at Month 3084.62
JIA ACR 70 at Month 3387.50
JIA ACR 70 at Month 3680.00
SecondaryPercentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 70 at Month 160.00
JIA ACR 70 at Month 367.63
JIA ACR 70 at Month 673.05
JIA ACR 70 at Month 971.83
JIA ACR 70 at Month 1273.05
JIA ACR 70 at Month 1578.36
JIA ACR 70 at Month 1875.20
JIA ACR 70 at Month 2177.05
JIA ACR 70 at Month 2482.88
JIA ACR 70 at Month 2780.00
JIA ACR 70 at Month 3078.70
JIA ACR 70 at Month 3382.88
JIA ACR 70 at Month 3686.24
JIA ACR 70 at Month 3980.19
JIA ACR 70 at Month 4282.00
JIA ACR 70 at Month 4586.81
JIA ACR 70 at Month 4887.50
JIA ACR 70 at Month 5188.06
JIA ACR 70 at Month 5492.73
JIA ACR 70 at Month 5788.68
JIA ACR 70 at Month 6082.61
JIA ACR 70 at Month 6390.24
JIA ACR 70 at Month 6684.62
JIA ACR 70 at Month 6992.50
JIA ACR 70 at Month 7289.74
JIA ACR 70 at Month 7585.29
JIA ACR 70 at Month 7885.71
SecondaryPercentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 70 at Month 158.33
JIA ACR 70 at Month 346.67
JIA ACR 70 at Month 676.47
JIA ACR 70 at Month 976.92
JIA ACR 70 at Month 1260.00
JIA ACR 70 at Month 1561.54
JIA ACR 70 at Month 1875.00
JIA ACR 70 at Month 2191.67
JIA ACR 70 at Month 2463.64
JIA ACR 70 at Month 2775.00
JIA ACR 70 at Month 3081.82
JIA ACR 70 at Month 3390.91
JIA ACR 70 at Month 3666.67
SecondaryPercentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR 70 response was defined as follows: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 70 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 70 at Month 152.94
JIA ACR 70 at Month 386.67
JIA ACR 70 at Month 673.33
JIA ACR 70 at Month 980.00
JIA ACR 70 at Month 1286.67
JIA ACR 70 at Month 1566.67
JIA ACR 70 at Month 1876.92
JIA ACR 70 at Month 2172.73
JIA ACR 70 at Month 2490.91
JIA ACR 70 at Month 2766.67
JIA ACR 70 at Month 3066.67
JIA ACR 70 at Month 3363.64
JIA ACR 70 at Month 3675.00
SecondaryPercentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 90 at Month 140.23
JIA ACR 90 at Month 351.19
JIA ACR 90 at Month 648.10
JIA ACR 90 at Month 949.35
JIA ACR 90 at Month 1248.33
JIA ACR 90 at Month 1543.75
JIA ACR 90 at Month 1851.28
JIA ACR 90 at Month 2144.83
JIA ACR 90 at Month 2451.85
JIA ACR 90 at Month 2766.67
JIA ACR 90 at Month 3058.82
JIA ACR 90 at Month 3358.33
JIA ACR 90 at Month 3644.44
SecondaryPercentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 90 at Month 142.86
JIA ACR 90 at Month 355.41
JIA ACR 90 at Month 650.00
JIA ACR 90 at Month 949.28
JIA ACR 90 at Month 1249.06
JIA ACR 90 at Month 1547.50
JIA ACR 90 at Month 1853.13
JIA ACR 90 at Month 2147.83
JIA ACR 90 at Month 2452.38
JIA ACR 90 at Month 2773.68
JIA ACR 90 at Month 3069.23
JIA ACR 90 at Month 3362.50
JIA ACR 90 at Month 3660.00
SecondaryPercentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 90 at Month 133.57
JIA ACR 90 at Month 336.99
JIA ACR 90 at Month 643.45
JIA ACR 90 at Month 948.25
JIA ACR 90 at Month 1245.00
JIA ACR 90 at Month 1554.48
JIA ACR 90 at Month 1849.60
JIA ACR 90 at Month 2148.33
JIA ACR 90 at Month 2454.05
JIA ACR 90 at Month 2755.86
JIA ACR 90 at Month 3056.48
JIA ACR 90 at Month 3363.06
JIA ACR 90 at Month 3665.45
JIA ACR 90 at Month 3962.96
JIA ACR 90 at Month 4261.39
JIA ACR 90 at Month 4565.93
JIA ACR 90 at Month 4864.20
JIA ACR 90 at Month 5166.67
JIA ACR 90 at Month 5464.29
JIA ACR 90 at Month 5759.26
JIA ACR 90 at Month 6058.70
JIA ACR 90 at Month 6363.41
JIA ACR 90 at Month 6661.54
JIA ACR 90 at Month 6965.00
JIA ACR 90 at Month 7264.10
JIA ACR 90 at Month 7565.71
JIA ACR 90 at Month 7860.71
SecondaryPercentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 90 at Month 130.77
JIA ACR 90 at Month 318.75
JIA ACR 90 at Month 633.33
JIA ACR 90 at Month 940.00
JIA ACR 90 at Month 1233.33
JIA ACR 90 at Month 1546.15
JIA ACR 90 at Month 1850.00
JIA ACR 90 at Month 2150.00
JIA ACR 90 at Month 2436.36
JIA ACR 90 at Month 2741.67
JIA ACR 90 at Month 3027.27
JIA ACR 90 at Month 3336.36
JIA ACR 90 at Month 3616.67
SecondaryPercentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR 90 response was defined as follows: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 90 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 90 at Month 144.44
JIA ACR 90 at Month 358.82
JIA ACR 90 at Month 653.33
JIA ACR 90 at Month 953.33
JIA ACR 90 at Month 1260.00
JIA ACR 90 at Month 1560.00
JIA ACR 90 at Month 1861.54
JIA ACR 90 at Month 2158.33
JIA ACR 90 at Month 2481.82
JIA ACR 90 at Month 2766.67
JIA ACR 90 at Month 3058.33
JIA ACR 90 at Month 3354.55
JIA ACR 90 at Month 3662.50
SecondaryPercentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 100 at Month 126.44
JIA ACR 100 at Month 336.90
JIA ACR 100 at Month 637.97
JIA ACR 100 at Month 932.47
JIA ACR 100 at Month 1231.67
JIA ACR 100 at Month 1535.42
JIA ACR 100 at Month 1846.15
JIA ACR 100 at Month 2141.38
JIA ACR 100 at Month 2444.44
JIA ACR 100 at Month 2745.83
JIA ACR 100 at Month 3052.94
JIA ACR 100 at Month 3325.00
JIA ACR 100 at Month 3644.44
SecondaryPercentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR. Assessment of fever was also included for participants with sJIA.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 100 at Month 127.27
JIA ACR 100 at Month 339.19
JIA ACR 100 at Month 638.89
JIA ACR 100 at Month 933.33
JIA ACR 100 at Month 1232.08
JIA ACR 100 at Month 1537.50
JIA ACR 100 at Month 1850.00
JIA ACR 100 at Month 2143.48
JIA ACR 100 at Month 2447.62
JIA ACR 100 at Month 2747.37
JIA ACR 100 at Month 3061.54
JIA ACR 100 at Month 3337.50
JIA ACR 100 at Month 3660.00
SecondaryPercentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 100 at Month 126.57
JIA ACR 100 at Month 329.93
JIA ACR 100 at Month 638.10
JIA ACR 100 at Month 939.86
JIA ACR 100 at Month 1240.29
JIA ACR 100 at Month 1546.67
JIA ACR 100 at Month 1841.94
JIA ACR 100 at Month 2139.67
JIA ACR 100 at Month 2445.95
JIA ACR 100 at Month 2747.27
JIA ACR 100 at Month 3047.71
JIA ACR 100 at Month 3348.65
JIA ACR 100 at Month 3657.27
JIA ACR 100 at Month 3950.00
JIA ACR 100 at Month 4248.51
JIA ACR 100 at Month 4551.09
JIA ACR 100 at Month 4852.50
JIA ACR 100 at Month 5157.97
JIA ACR 100 at Month 5455.36
JIA ACR 100 at Month 5755.56
JIA ACR 100 at Month 6056.52
JIA ACR 100 at Month 6357.50
JIA ACR 100 at Month 6656.41
JIA ACR 100 at Month 6958.97
JIA ACR 100 at Month 7261.54
JIA ACR 100 at Month 7554.29
JIA ACR 100 at Month 7857.14
SecondaryPercentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 100 at Month 128.57
JIA ACR 100 at Month 317.65
JIA ACR 100 at Month 633.33
JIA ACR 100 at Month 933.33
JIA ACR 100 at Month 1226.67
JIA ACR 100 at Month 1546.15
JIA ACR 100 at Month 1833.33
JIA ACR 100 at Month 2141.67
JIA ACR 100 at Month 2427.27
JIA ACR 100 at Month 2741.67
JIA ACR 100 at Month 3027.27
JIA ACR 100 at Month 3336.36
JIA ACR 100 at Month 3616.67
SecondaryPercentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR 100 response was defined as follows: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. JIA core set variables: 1) Physician global evaluation of disease activity (0 \[no disease activity\] to 10 \[maximum disease activity\]), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]), 5) Functional ability using disability index from CHAQ (0 \[very well\] to 10 \[very poor\]), 6) ESR.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a JIA ACR 100 Response at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR 100 at Month 138.89
JIA ACR 100 at Month 341.18
JIA ACR 100 at Month 653.33
JIA ACR 100 at Month 940.00
JIA ACR 100 at Month 1233.33
JIA ACR 100 at Month 1553.33
JIA ACR 100 at Month 1846.15
JIA ACR 100 at Month 2158.33
JIA ACR 100 at Month 2481.82
JIA ACR 100 at Month 2766.67
JIA ACR 100 at Month 3058.33
JIA ACR 100 at Month 3354.55
JIA ACR 100 at Month 3662.50
SecondaryPercentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree Celsius(C) oral or \>38.6 degree C rectal on \>=2 consecutive days.

Time frame:
At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Disease flare at Month 65.0
Disease flare at Month 99.3
Disease flare at Month 121.7
Disease flare at Month 158.2
Disease flare at Month 187.9
Disease flare at Month 210
Disease flare at Month 2411.5
Disease flare at Month 274.3
Disease flare at Month 300
Disease flare at Month 330
Disease flare at Month 360
SecondaryPercentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal. Participants with sJIA: might include recurrence of fever due to sJIA \>38 degree C oral or \>38.6 degree C rectal on \>=2 consecutive days.

Time frame:
At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Disease flare at Month 65.6
Disease flare at Month 910.1
Disease flare at Month 121.9
Disease flare at Month 159.8
Disease flare at Month 186.3
Disease flare at Month 210
Disease flare at Month 2414.3
Disease flare at Month 275.3
Disease flare at Month 300
Disease flare at Month 330
Disease flare at Month 360
SecondaryPercentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

Time frame:
At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Disease flare at Month 63.9
Disease flare at Month 94.8
Disease flare at Month 125.6
Disease flare at Month 153.6
Disease flare at Month 182.3
Disease flare at Month 213.9
Disease flare at Month 241.8
Disease flare at Month 274.3
Disease flare at Month 302.7
Disease flare at Month 332.7
Disease flare at Month 360.9
Disease flare at Month 394.8
Disease flare at Month 421.9
Disease flare at Month 451.1
Disease flare at Month 481.3
Disease flare at Month 512.9
Disease flare at Month 541.8
Disease flare at Month 571.9
Disease flare at Month 604.5
Disease flare at Month 632.5
Disease flare at Month 665.7
Disease flare at Month 690
Disease flare at Month 725.4
Disease flare at Month 753.1
Disease flare at Month 780
SecondaryPercentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

Time frame:
At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Disease flare at Month 65.9
Disease flare at Month 90
Disease flare at Month 120
Disease flare at Month 150
Disease flare at Month 180
Disease flare at Month 210
Disease flare at Month 248.3
Disease flare at Month 279.1
Disease flare at Month 300
Disease flare at Month 330
Disease flare at Month 369.1
SecondaryPercentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

Disease flare: worsening of \>=30% in 3 or more of 6 variables of JIA core set, with no more than 1 variable improved by \>=30%. Variables: 1) Physician global evaluation of disease activity (0= no disease activity - 10= maximum disease activity), 2) Number of joints with active arthritis, 3) Number of joints with limited range of motion, 4) Parent/legal guardian/participant evaluation of overall well-being using CHAQ (0= very well - 10= very poor), 5) Functional ability using disability index from CHAQ (0= very well - 10= very poor), 6) ESR. Fare definition: for number of active joints or joints with limited range of motion: at least 2 joints must have worsened; for physician's or parent/legal guardian global rating scores: at least 2 units worsening on 10-unit scale; for ESR: 2nd value for ESR in calculation \>upper limit of normal.

Time frame:
At Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Disease Flare After Month 3 at Months 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Disease flare at Month 60
Disease flare at Month 97.1
Disease flare at Month 126.7
Disease flare at Month 150
Disease flare at Month 180
Disease flare at Month 218.3
Disease flare at Month 249.1
Disease flare at Month 278.3
Disease flare at Month 307.7
Disease flare at Month 330
Disease flare at Month 3610.0
SecondaryPercentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Inactive Disease Based on CRP: Month 113.79
JIA ACR Clinical Inactive Disease Based on CRP: Month 316.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 617.72
JIA ACR Clinical Inactive Disease Based on CRP: Month 919.74
JIA ACR Clinical Inactive Disease Based on CRP: Month 1225.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 1525.53
JIA ACR Clinical Inactive Disease Based on CRP: Month 1835.90
JIA ACR Clinical Inactive Disease Based on CRP: Month 2132.14
JIA ACR Clinical Inactive Disease Based on CRP: Month 2429.63
JIA ACR Clinical Inactive Disease Based on CRP: Month 2734.78
JIA ACR Clinical Inactive Disease Based on CRP: Month 3041.18
JIA ACR Clinical Inactive Disease Based on CRP: Month 3316.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 3633.33
JIA ACR Clinical Inactive Disease Based on ESR: Month 117.05
JIA ACR Clinical Inactive Disease Based on ESR: Month 319.05
JIA ACR Clinical Inactive Disease Based on ESR: Month 620.25
JIA ACR Clinical Inactive Disease Based on ESR: Month 919.74
JIA ACR Clinical Inactive Disease Based on ESR: Month 1226.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 1527.08
JIA ACR Clinical Inactive Disease Based on ESR: Month 1835.90
JIA ACR Clinical Inactive Disease Based on ESR: Month 2137.93
JIA ACR Clinical Inactive Disease Based on ESR: Month 2433.33
JIA ACR Clinical Inactive Disease Based on ESR: Month 2733.33
JIA ACR Clinical Inactive Disease Based on ESR: Month 3041.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 3325.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 3633.33
SecondaryPercentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Inactive Disease Based on CRP: Month 114.47
JIA ACR Clinical Inactive Disease Based on CRP: Month 316.44
JIA ACR Clinical Inactive Disease Based on CRP: Month 616.90
JIA ACR Clinical Inactive Disease Based on CRP: Month 919.12
JIA ACR Clinical Inactive Disease Based on CRP: Month 1224.53
JIA ACR Clinical Inactive Disease Based on CRP: Month 1525.64
JIA ACR Clinical Inactive Disease Based on CRP: Month 1837.50
JIA ACR Clinical Inactive Disease Based on CRP: Month 2131.82
JIA ACR Clinical Inactive Disease Based on CRP: Month 2433.33
JIA ACR Clinical Inactive Disease Based on CRP: Month 2738.89
JIA ACR Clinical Inactive Disease Based on CRP: Month 3053.85
JIA ACR Clinical Inactive Disease Based on CRP: Month 3325.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 3640.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 118.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 319.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 619.72
JIA ACR Clinical Inactive Disease Based on ESR: Month 919.12
JIA ACR Clinical Inactive Disease Based on ESR: Month 1226.42
JIA ACR Clinical Inactive Disease Based on ESR: Month 1527.50
JIA ACR Clinical Inactive Disease Based on ESR: Month 1840.63
JIA ACR Clinical Inactive Disease Based on ESR: Month 2143.48
JIA ACR Clinical Inactive Disease Based on ESR: Month 2438.10
JIA ACR Clinical Inactive Disease Based on ESR: Month 2736.84
JIA ACR Clinical Inactive Disease Based on ESR: Month 3053.85
JIA ACR Clinical Inactive Disease Based on ESR: Month 3337.50
JIA ACR Clinical Inactive Disease Based on ESR: Month 3640.00
SecondaryPercentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Inactive Disease Based on CRP: Month 122.22
JIA ACR Clinical Inactive Disease Based on CRP: Month 328.09
JIA ACR Clinical Inactive Disease Based on CRP: Month 630.12
JIA ACR Clinical Inactive Disease Based on CRP: Month 932.91
JIA ACR Clinical Inactive Disease Based on CRP: Month 1231.41
JIA ACR Clinical Inactive Disease Based on CRP: Month 1533.56
JIA ACR Clinical Inactive Disease Based on CRP: Month 1833.82
JIA ACR Clinical Inactive Disease Based on CRP: Month 2135.61
JIA ACR Clinical Inactive Disease Based on CRP: Month 2438.02
JIA ACR Clinical Inactive Disease Based on CRP: Month 2742.50
JIA ACR Clinical Inactive Disease Based on CRP: Month 3047.46
JIA ACR Clinical Inactive Disease Based on CRP: Month 3341.03
JIA ACR Clinical Inactive Disease Based on CRP: Month 3644.54
JIA ACR Clinical Inactive Disease Based on CRP: Month 3942.61
JIA ACR Clinical Inactive Disease Based on CRP: Month 4243.75
JIA ACR Clinical Inactive Disease Based on CRP: Month 4544.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 4844.32
JIA ACR Clinical Inactive Disease Based on CRP: Month 5143.42
JIA ACR Clinical Inactive Disease Based on CRP: Month 5446.15
JIA ACR Clinical Inactive Disease Based on CRP: Month 5748.39
JIA ACR Clinical Inactive Disease Based on CRP: Month 6050.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 6348.89
JIA ACR Clinical Inactive Disease Based on CRP: Month 6640.91
JIA ACR Clinical Inactive Disease Based on CRP: Month 6948.84
JIA ACR Clinical Inactive Disease Based on CRP: Month 7250.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 7544.74
JIA ACR Clinical Inactive Disease Based on CRP: Month 7840.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 123.76
JIA ACR Clinical Inactive Disease Based on ESR: Month 328.65
JIA ACR Clinical Inactive Disease Based on ESR: Month 630.12
JIA ACR Clinical Inactive Disease Based on ESR: Month 935.44
JIA ACR Clinical Inactive Disease Based on ESR: Month 1232.05
JIA ACR Clinical Inactive Disease Based on ESR: Month 1535.62
JIA ACR Clinical Inactive Disease Based on ESR: Month 1835.56
JIA ACR Clinical Inactive Disease Based on ESR: Month 2136.57
JIA ACR Clinical Inactive Disease Based on ESR: Month 2438.02
JIA ACR Clinical Inactive Disease Based on ESR: Month 2740.34
JIA ACR Clinical Inactive Disease Based on ESR: Month 3043.59
JIA ACR Clinical Inactive Disease Based on ESR: Month 3339.83
JIA ACR Clinical Inactive Disease Based on ESR: Month 3644.92
JIA ACR Clinical Inactive Disease Based on ESR: Month 3941.74
JIA ACR Clinical Inactive Disease Based on ESR: Month 4241.96
JIA ACR Clinical Inactive Disease Based on ESR: Month 4542.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 4843.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 5146.05
JIA ACR Clinical Inactive Disease Based on ESR: Month 5447.69
JIA ACR Clinical Inactive Disease Based on ESR: Month 5745.16
JIA ACR Clinical Inactive Disease Based on ESR: Month 6045.10
JIA ACR Clinical Inactive Disease Based on ESR: Month 6350.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 6643.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 6945.45
JIA ACR Clinical Inactive Disease Based on ESR: Month 7251.16
JIA ACR Clinical Inactive Disease Based on ESR: Month 7547.50
JIA ACR Clinical Inactive Disease Based on ESR: Month 7848.48
SecondaryPercentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Inactive Disease Based on CRP: Month 120.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 319.05
JIA ACR Clinical Inactive Disease Based on CRP: Month 631.58
JIA ACR Clinical Inactive Disease Based on CRP: Month 926.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 1226.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 1538.46
JIA ACR Clinical Inactive Disease Based on CRP: Month 1850.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 2136.36
JIA ACR Clinical Inactive Disease Based on CRP: Month 2418.18
JIA ACR Clinical Inactive Disease Based on CRP: Month 2733.33
JIA ACR Clinical Inactive Disease Based on CRP: Month 3027.27
JIA ACR Clinical Inactive Disease Based on CRP: Month 3325.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 3625.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 120.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 319.05
JIA ACR Clinical Inactive Disease Based on ESR: Month 631.58
JIA ACR Clinical Inactive Disease Based on ESR: Month 926.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 1233.33
JIA ACR Clinical Inactive Disease Based on ESR: Month 1538.46
JIA ACR Clinical Inactive Disease Based on ESR: Month 1850.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 2141.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 2418.18
JIA ACR Clinical Inactive Disease Based on ESR: Month 2727.27
JIA ACR Clinical Inactive Disease Based on ESR: Month 3027.27
JIA ACR Clinical Inactive Disease Based on ESR: Month 3325.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 3625.00
SecondaryPercentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR clinical inactive disease status was defined as achieving all the following criteria: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; ESR or CRP within the normal reference range for the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Inactive Disease Status Based on CRP and ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Inactive Disease Based on CRP: Month 122.22
JIA ACR Clinical Inactive Disease Based on CRP: Month 311.11
JIA ACR Clinical Inactive Disease Based on CRP: Month 633.33
JIA ACR Clinical Inactive Disease Based on CRP: Month 926.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 1218.75
JIA ACR Clinical Inactive Disease Based on CRP: Month 1526.67
JIA ACR Clinical Inactive Disease Based on CRP: Month 1838.46
JIA ACR Clinical Inactive Disease Based on CRP: Month 2138.46
JIA ACR Clinical Inactive Disease Based on CRP: Month 2445.45
JIA ACR Clinical Inactive Disease Based on CRP: Month 2718.18
JIA ACR Clinical Inactive Disease Based on CRP: Month 3053.85
JIA ACR Clinical Inactive Disease Based on CRP: Month 3350.00
JIA ACR Clinical Inactive Disease Based on CRP: Month 3622.22
JIA ACR Clinical Inactive Disease Based on ESR: Month 122.22
JIA ACR Clinical Inactive Disease Based on ESR: Month 316.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 626.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 926.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 1212.50
JIA ACR Clinical Inactive Disease Based on ESR: Month 1526.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 1830.77
JIA ACR Clinical Inactive Disease Based on ESR: Month 2141.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 2450.00
JIA ACR Clinical Inactive Disease Based on ESR: Month 2716.67
JIA ACR Clinical Inactive Disease Based on ESR: Month 3046.15
JIA ACR Clinical Inactive Disease Based on ESR: Month 3345.45
JIA ACR Clinical Inactive Disease Based on ESR: Month 3611.11
SecondaryPercentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the standardization of uveitis nomenclature \[SUN\] working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

Time frame:
At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Remission Based on CRP: Month 97.89
JIA ACR Clinical Remission Based on CRP: Month 125.00
JIA ACR Clinical Remission Based on CRP: Month 154.26
JIA ACR Clinical Remission Based on CRP: Month 1810.26
JIA ACR Clinical Remission Based on CRP: Month 210
JIA ACR Clinical Remission Based on CRP: Month 240
JIA ACR Clinical Remission Based on CRP: Month 278.70
JIA ACR Clinical Remission Based on CRP: Month 300
JIA ACR Clinical Remission Based on CRP: Month 330
JIA ACR Clinical Remission Based on CRP: Month 360
JIA ACR Clinical Remission Based on ESR: Month 99.21
JIA ACR Clinical Remission Based on ESR: Month 123.33
JIA ACR Clinical Remission Based on ESR: Month 154.17
JIA ACR Clinical Remission Based on ESR: Month 1810.26
JIA ACR Clinical Remission Based on ESR: Month 210
JIA ACR Clinical Remission Based on ESR: Month 2411.11
JIA ACR Clinical Remission Based on ESR: Month 274.17
JIA ACR Clinical Remission Based on ESR: Month 300
JIA ACR Clinical Remission Based on ESR: Month 330
JIA ACR Clinical Remission Based on ESR: Month 360
SecondaryPercentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

Time frame:
At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Remission Based on CRP: Month 98.82
JIA ACR Clinical Remission Based on CRP: Month 123.77
JIA ACR Clinical Remission Based on CRP: Month 155.13
JIA ACR Clinical Remission Based on CRP: Month 189.38
JIA ACR Clinical Remission Based on CRP: Month 210
JIA ACR Clinical Remission Based on CRP: Month 240
JIA ACR Clinical Remission Based on CRP: Month 2711.11
JIA ACR Clinical Remission Based on CRP: Month 300
JIA ACR Clinical Remission Based on CRP: Month 330
JIA ACR Clinical Remission Based on CRP: Month 360
JIA ACR Clinical Remission Based on ESR: Month 910.29
JIA ACR Clinical Remission Based on ESR: Month 121.89
JIA ACR Clinical Remission Based on ESR: Month 155.00
JIA ACR Clinical Remission Based on ESR: Month 189.38
JIA ACR Clinical Remission Based on ESR: Month 210
JIA ACR Clinical Remission Based on ESR: Month 2414.29
JIA ACR Clinical Remission Based on ESR: Month 275.26
JIA ACR Clinical Remission Based on ESR: Month 300
JIA ACR Clinical Remission Based on ESR: Month 330
JIA ACR Clinical Remission Based on ESR: Month 360
SecondaryPercentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

Time frame:
At Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Remission Based on CRP: Month 918.35
JIA ACR Clinical Remission Based on CRP: Month 124.49
JIA ACR Clinical Remission Based on CRP: Month 153.42
JIA ACR Clinical Remission Based on CRP: Month 185.15
JIA ACR Clinical Remission Based on CRP: Month 212.27
JIA ACR Clinical Remission Based on CRP: Month 243.31
JIA ACR Clinical Remission Based on CRP: Month 274.17
JIA ACR Clinical Remission Based on CRP: Month 301.69
JIA ACR Clinical Remission Based on CRP: Month 331.71
JIA ACR Clinical Remission Based on CRP: Month 360.84
JIA ACR Clinical Remission Based on CRP: Month 390.87
JIA ACR Clinical Remission Based on CRP: Month 421.79
JIA ACR Clinical Remission Based on CRP: Month 450
JIA ACR Clinical Remission Based on CRP: Month 483.41
JIA ACR Clinical Remission Based on CRP: Month 510
JIA ACR Clinical Remission Based on CRP: Month 540
JIA ACR Clinical Remission Based on CRP: Month 570
JIA ACR Clinical Remission Based on CRP: Month 605.77
JIA ACR Clinical Remission Based on CRP: Month 630
JIA ACR Clinical Remission Based on CRP: Month 662.27
JIA ACR Clinical Remission Based on CRP: Month 690
JIA ACR Clinical Remission Based on CRP: Month 720
JIA ACR Clinical Remission Based on CRP: Month 750
JIA ACR Clinical Remission Based on CRP: Month 780
JIA ACR Clinical Remission Based on ESR: Month 919.62
JIA ACR Clinical Remission Based on ESR: Month 125.13
JIA ACR Clinical Remission Based on ESR: Month 155.48
JIA ACR Clinical Remission Based on ESR: Month 185.19
JIA ACR Clinical Remission Based on ESR: Month 211.49
JIA ACR Clinical Remission Based on ESR: Month 243.31
JIA ACR Clinical Remission Based on ESR: Month 271.68
JIA ACR Clinical Remission Based on ESR: Month 300.85
JIA ACR Clinical Remission Based on ESR: Month 330.85
JIA ACR Clinical Remission Based on ESR: Month 360
JIA ACR Clinical Remission Based on ESR: Month 391.74
JIA ACR Clinical Remission Based on ESR: Month 421.79
JIA ACR Clinical Remission Based on ESR: Month 450
JIA ACR Clinical Remission Based on ESR: Month 482.27
JIA ACR Clinical Remission Based on ESR: Month 511.32
JIA ACR Clinical Remission Based on ESR: Month 540
JIA ACR Clinical Remission Based on ESR: Month 570
JIA ACR Clinical Remission Based on ESR: Month 605.88
JIA ACR Clinical Remission Based on ESR: Month 630
JIA ACR Clinical Remission Based on ESR: Month 660
JIA ACR Clinical Remission Based on ESR: Month 692.27
JIA ACR Clinical Remission Based on ESR: Month 720
JIA ACR Clinical Remission Based on ESR: Month 750
JIA ACR Clinical Remission Based on ESR: Month 780
SecondaryPercentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

Time frame:
At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Remission Based on CRP: Month 913.33
JIA ACR Clinical Remission Based on CRP: Month 126.67
JIA ACR Clinical Remission Based on CRP: Month 150
JIA ACR Clinical Remission Based on CRP: Month 188.33
JIA ACR Clinical Remission Based on CRP: Month 2118.18
JIA ACR Clinical Remission Based on CRP: Month 240
JIA ACR Clinical Remission Based on CRP: Month 270
JIA ACR Clinical Remission Based on CRP: Month 300
JIA ACR Clinical Remission Based on CRP: Month 330
JIA ACR Clinical Remission Based on CRP: Month 360
JIA ACR Clinical Remission Based on ESR: Month 913.33
JIA ACR Clinical Remission Based on ESR: Month 126.67
JIA ACR Clinical Remission Based on ESR: Month 150
JIA ACR Clinical Remission Based on ESR: Month 1816.67
JIA ACR Clinical Remission Based on ESR: Month 218.33
JIA ACR Clinical Remission Based on ESR: Month 240
JIA ACR Clinical Remission Based on ESR: Month 270
JIA ACR Clinical Remission Based on ESR: Month 300
JIA ACR Clinical Remission Based on ESR: Month 330
JIA ACR Clinical Remission Based on ESR: Month 360
SecondaryPercentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JIA ACR clinical remission was defined as inactive disease for 6 months (24 weeks) continuously while on medications. Clinical inactive disease status determination assessment was a derived measurement, which includes: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis (as defined by the SUN working group); ESR or CRP levels within normal limits in the laboratory where tested or, if elevated, not attributable to JIA; physician global evaluation of disease activity score of 'best possible' on the scale used (0= no disease activity - 10= maximum disease activity); duration of morning stiffness of \<=15 minutes. At each time point, percentage of participants achieving clinical remission for the first time is reported.

Time frame:
At Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR Clinical Remission Based on CRP and ESR at Months 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JIA ACR Clinical Remission Based on CRP: Month 96.67
JIA ACR Clinical Remission Based on CRP: Month 120
JIA ACR Clinical Remission Based on CRP: Month 156.67
JIA ACR Clinical Remission Based on CRP: Month 187.69
JIA ACR Clinical Remission Based on CRP: Month 2115.38
JIA ACR Clinical Remission Based on CRP: Month 240
JIA ACR Clinical Remission Based on CRP: Month 270
JIA ACR Clinical Remission Based on CRP: Month 307.69
JIA ACR Clinical Remission Based on CRP: Month 330
JIA ACR Clinical Remission Based on CRP: Month 360
JIA ACR Clinical Remission Based on ESR: Month 96.67
JIA ACR Clinical Remission Based on ESR: Month 120
JIA ACR Clinical Remission Based on ESR: Month 156.67
JIA ACR Clinical Remission Based on ESR: Month 180
JIA ACR Clinical Remission Based on ESR: Month 218.33
JIA ACR Clinical Remission Based on ESR: Month 240
JIA ACR Clinical Remission Based on ESR: Month 270
JIA ACR Clinical Remission Based on ESR: Month 307.69
JIA ACR Clinical Remission Based on ESR: Month 330
JIA ACR Clinical Remission Based on ESR: Month 360
SecondaryChange From Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-16.58 ± 9.48
Change at Month 3-17.82 ± 9.53
Change at Month 6-19.46 ± 8.28
Change at Month 9-19.07 ± 8.53
Change at Month 12-20.11 ± 8.96
Change at Month 15-18.25 ± 9.63
Change at Month 18-18.91 ± 10.42
Change at Month 21-20.28 ± 9.46
Change at Month 24-20.22 ± 9.32
Change at Month 27-19.92 ± 10.94
Change at Month 30-21.35 ± 10.96
Change at Month 33-19.07 ± 9.74
Change at Month 36-19.29 ± 10.49
SecondaryChange From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-16.86 ± 9.46
Change at Month 3-18.72 ± 8.55
Change at Month 6-19.36 ± 8.01
Change at Month 9-19.05 ± 8.09
Change at Month 12-19.91 ± 8.83
Change at Month 15-18.49 ± 9.12
Change at Month 18-19.14 ± 9.95
Change at Month 21-20.26 ± 9.02
Change at Month 24-20.62 ± 8.19
Change at Month 27-20.05 ± 10.10
Change at Month 30-22.34 ± 9.84
Change at Month 33-18.93 ± 8.05
Change at Month 36-17.65 ± 9.27
SecondaryChange From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-15.45 ± 8.20
Change at Month 3-16.29 ± 8.81
Change at Month 6-17.42 ± 8.11
Change at Month 9-17.17 ± 8.05
Change at Month 12-17.81 ± 8.06
Change at Month 15-18.00 ± 8.23
Change at Month 18-18.17 ± 8.85
Change at Month 21-18.15 ± 8.44
Change at Month 24-18.61 ± 8.21
Change at Month 27-18.61 ± 7.62
Change at Month 30-18.49 ± 8.30
Change at Month 33-18.22 ± 7.70
Change at Month 36-18.75 ± 8.05
Change at Month 39-17.85 ± 8.22
Change at Month 42-18.67 ± 7.64
Change at Month 45-18.28 ± 7.55
Change at Month 48-19.06 ± 7.82
Change at Month 51-18.52 ± 7.84
Change at Month 54-18.62 ± 6.51
Change at Month 57-18.48 ± 7.16
Change at Month 60-17.66 ± 6.86
Change at Month 63-19.12 ± 8.00
Change at Month 66-17.17 ± 7.23
Change at Month 69-18.63 ± 7.74
Change at Month 72-17.96 ± 8.26
Change at Month 75-18.36 ± 7.27
Change at Month 78-19.76 ± 7.45
SecondaryChange From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-8.80 ± 4.54
Change at Month 3-8.49 ± 3.82
Change at Month 6-9.61 ± 4.05
Change at Month 9-11.23 ± 2.70
Change at Month 12-10.16 ± 2.99
Change at Month 15-11.12 ± 3.48
Change at Month 18-11.78 ± 3.11
Change at Month 21-12.30 ± 3.27
Change at Month 24-10.75 ± 4.77
Change at Month 27-10.91 ± 3.33
Change at Month 30-11.46 ± 2.99
Change at Month 33-11.42 ± 3.19
Change at Month 36-11.27 ± 3.26
SecondaryChange From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 CRP at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-12.55 ± 8.09
Change at Month 3-13.69 ± 7.65
Change at Month 6-14.62 ± 6.43
Change at Month 9-14.08 ± 6.48
Change at Month 12-14.51 ± 7.48
Change at Month 15-13.58 ± 7.56
Change at Month 18-13.84 ± 9.87
Change at Month 21-14.93 ± 8.50
Change at Month 24-16.07 ± 8.55
Change at Month 27-15.50 ± 7.95
Change at Month 30-15.27 ± 7.53
Change at Month 33-14.45 ± 6.96
Change at Month 36-14.32 ± 7.11
SecondaryChange From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-16.98 ± 9.18
Change at Month 3-18.33 ± 9.69
Change at Month 6-20.06 ± 7.81
Change at Month 9-19.38 ± 8.49
Change at Month 12-20.02 ± 9.29
Change at Month 15-17.94 ± 9.81
Change at Month 18-18.50 ± 10.54
Change at Month 21-20.29 ± 9.70
Change at Month 24-20.12 ± 9.65
Change at Month 27-19.72 ± 10.70
Change at Month 30-20.61 ± 10.01
Change at Month 33-18.77 ± 9.20
Change at Month 36-19.04 ± 10.08
SecondaryChange From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-17.22 ± 9.01
Change at Month 3-19.16 ± 8.70
Change at Month 6-19.97 ± 7.38
Change at Month 9-19.32 ± 7.98
Change at Month 12-19.85 ± 8.97
Change at Month 15-17.86 ± 9.28
Change at Month 18-18.89 ± 10.14
Change at Month 21-20.13 ± 9.04
Change at Month 24-20.21 ± 8.24
Change at Month 27-19.40 ± 9.59
Change at Month 30-21.48 ± 8.54
Change at Month 33-19.25 ± 7.29
Change at Month 36-17.28 ± 9.41
SecondaryChange From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78: Participants in pJIA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-15.30 ± 8.29
Change at Month 3-16.39 ± 8.89
Change at Month 6-17.39 ± 8.22
Change at Month 9-17.25 ± 8.09
Change at Month 12-17.73 ± 8.25
Change at Month 15-18.00 ± 7.96
Change at Month 18-18.00 ± 8.50
Change at Month 21-18.18 ± 8.35
Change at Month 24-18.41 ± 8.03
Change at Month 27-18.84 ± 7.61
Change at Month 30-18.09 ± 8.21
Change at Month 33-17.95 ± 7.44
Change at Month 36-18.46 ± 7.99
Change at Month 39-17.34 ± 8.17
Change at Month 42-18.18 ± 7.50
Change at Month 45-18.36 ± 7.66
Change at Month 48-18.72 ± 7.65
Change at Month 51-18.00 ± 7.49
Change at Month 54-18.91 ± 6.73
Change at Month 57-17.85 ± 6.89
Change at Month 60-17.16 ± 7.44
Change at Month 63-17.97 ± 7.22
Change at Month 66-16.95 ± 7.62
Change at Month 69-17.83 ± 7.54
Change at Month 72-17.35 ± 7.74
Change at Month 75-17.61 ± 8.02
Change at Month 78-18.45 ± 7.83
SecondaryChange From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-8.95 ± 4.93
Change at Month 3-8.76 ± 4.21
Change at Month 6-10.11 ± 4.13
Change at Month 9-11.51 ± 2.76
Change at Month 12-10.30 ± 3.20
Change at Month 15-11.48 ± 3.48
Change at Month 18-12.20 ± 3.34
Change at Month 21-12.63 ± 3.40
Change at Month 24-10.95 ± 4.95
Change at Month 27-9.92 ± 4.35
Change at Month 30-11.71 ± 3.16
Change at Month 33-11.65 ± 3.42
Change at Month 36-11.49 ± 3.56
SecondaryChange From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · Units on a scale
Change From Baseline in JADAS-27 ESR at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Units on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 1-13.73 ± 7.09
Change at Month 3-13.96 ± 7.11
Change at Month 6-15.02 ± 5.44
Change at Month 9-14.58 ± 5.76
Change at Month 12-14.90 ± 6.69
Change at Month 15-14.25 ± 6.89
Change at Month 18-14.86 ± 8.09
Change at Month 21-15.59 ± 8.14
Change at Month 24-15.48 ± 7.94
Change at Month 27-16.02 ± 7.21
Change at Month 30-15.08 ± 7.61
Change at Month 33-14.58 ± 6.03
Change at Month 36-14.00 ± 6.84
SecondaryPercentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Minimum Disease Activity: Month 143.2
JADAS-27 CRP Minimum Disease Activity: Month 355.6
JADAS-27 CRP Minimum Disease Activity: Month 656.4
JADAS-27 CRP Minimum Disease Activity: Month 955.3
JADAS-27 CRP Minimum Disease Activity: Month 1254.2
JADAS-27 CRP Minimum Disease Activity: Month 1548.9
JADAS-27 CRP Minimum Disease Activity: Month 1850.0
JADAS-27 CRP Minimum Disease Activity: Month 2153.6
JADAS-27 CRP Minimum Disease Activity: Month 2451.9
JADAS-27 CRP Minimum Disease Activity: Month 2756.5
JADAS-27 CRP Minimum Disease Activity: Month 3058.8
JADAS-27 CRP Minimum Disease Activity: Month 3354.5
JADAS-27 CRP Minimum Disease Activity: Month 3666.7
JADAS-27 ESR Minimum Disease Activity: Month 147.6
JADAS-27 ESR Minimum Disease Activity: Month 354.9
JADAS-27 ESR Minimum Disease Activity: Month 659.0
JADAS-27 ESR Minimum Disease Activity: Month 953.9
JADAS-27 ESR Minimum Disease Activity: Month 1251.7
JADAS-27 ESR Minimum Disease Activity: Month 1546.8
JADAS-27 ESR Minimum Disease Activity: Month 1847.4
JADAS-27 ESR Minimum Disease Activity: Month 2151.7
JADAS-27 ESR Minimum Disease Activity: Month 2440.7
JADAS-27 ESR Minimum Disease Activity: Month 2762.5
JADAS-27 ESR Minimum Disease Activity: Month 3052.9
JADAS-27 ESR Minimum Disease Activity: Month 3341.7
JADAS-27 ESR Minimum Disease Activity: Month 3644.4
SecondaryPercentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Minimum Disease Activity: Month 143.2
JADAS-27 CRP Minimum Disease Activity: Month 357.5
JADAS-27 CRP Minimum Disease Activity: Month 655.6
JADAS-27 CRP Minimum Disease Activity: Month 955.1
JADAS-27 CRP Minimum Disease Activity: Month 1251.9
JADAS-27 CRP Minimum Disease Activity: Month 1548.7
JADAS-27 CRP Minimum Disease Activity: Month 1853.1
JADAS-27 CRP Minimum Disease Activity: Month 2154.5
JADAS-27 CRP Minimum Disease Activity: Month 2457.1
JADAS-27 CRP Minimum Disease Activity: Month 2755.6
JADAS-27 CRP Minimum Disease Activity: Month 3069.2
JADAS-27 CRP Minimum Disease Activity: Month 3371.4
JADAS-27 CRP Minimum Disease Activity: Month 3680.0
JADAS-27 ESR Minimum Disease Activity: Month 148.1
JADAS-27 ESR Minimum Disease Activity: Month 356.8
JADAS-27 ESR Minimum Disease Activity: Month 658.3
JADAS-27 ESR Minimum Disease Activity: Month 955.1
JADAS-27 ESR Minimum Disease Activity: Month 1251.0
JADAS-27 ESR Minimum Disease Activity: Month 1546.2
JADAS-27 ESR Minimum Disease Activity: Month 1851.6
JADAS-27 ESR Minimum Disease Activity: Month 2152.2
JADAS-27 ESR Minimum Disease Activity: Month 2447.6
JADAS-27 ESR Minimum Disease Activity: Month 2763.2
JADAS-27 ESR Minimum Disease Activity: Month 3061.5
JADAS-27 ESR Minimum Disease Activity: Month 3362.5
JADAS-27 ESR Minimum Disease Activity: Month 3640.0
SecondaryPercentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Minimum Disease Activity: Month 152.0
JADAS-27 CRP Minimum Disease Activity: Month 358.1
JADAS-27 CRP Minimum Disease Activity: Month 661.4
JADAS-27 CRP Minimum Disease Activity: Month 958.7
JADAS-27 CRP Minimum Disease Activity: Month 1266.0
JADAS-27 CRP Minimum Disease Activity: Month 1566.4
JADAS-27 CRP Minimum Disease Activity: Month 1870.4
JADAS-27 CRP Minimum Disease Activity: Month 2167.5
JADAS-27 CRP Minimum Disease Activity: Month 2464.3
JADAS-27 CRP Minimum Disease Activity: Month 2770.1
JADAS-27 CRP Minimum Disease Activity: Month 3067.9
JADAS-27 CRP Minimum Disease Activity: Month 3370.5
JADAS-27 CRP Minimum Disease Activity: Month 3671.8
JADAS-27 CRP Minimum Disease Activity: Month 3968.2
JADAS-27 CRP Minimum Disease Activity: Month 4275.2
JADAS-27 CRP Minimum Disease Activity: Month 4570.0
JADAS-27 CRP Minimum Disease Activity: Month 4874.4
JADAS-27 CRP Minimum Disease Activity: Month 5174.6
JADAS-27 CRP Minimum Disease Activity: Month 5471.7
JADAS-27 CRP Minimum Disease Activity: Month 5772.4
JADAS-27 CRP Minimum Disease Activity: Month 6065.3
JADAS-27 CRP Minimum Disease Activity: Month 6372.7
JADAS-27 CRP Minimum Disease Activity: Month 6672.1
JADAS-27 CRP Minimum Disease Activity: Month 6974.4
JADAS-27 CRP Minimum Disease Activity: Month 7269.0
JADAS-27 CRP Minimum Disease Activity: Month 7573.0
JADAS-27 CRP Minimum Disease Activity: Month 7882.1
JADAS-27 ESR Minimum Disease Activity: Month 152.5
JADAS-27 ESR Minimum Disease Activity: Month 354.5
JADAS-27 ESR Minimum Disease Activity: Month 658.8
JADAS-27 ESR Minimum Disease Activity: Month 955.7
JADAS-27 ESR Minimum Disease Activity: Month 1261.2
JADAS-27 ESR Minimum Disease Activity: Month 1563.9
JADAS-27 ESR Minimum Disease Activity: Month 1868.0
JADAS-27 ESR Minimum Disease Activity: Month 2161.3
JADAS-27 ESR Minimum Disease Activity: Month 2461.3
JADAS-27 ESR Minimum Disease Activity: Month 2769.4
JADAS-27 ESR Minimum Disease Activity: Month 3064.2
JADAS-27 ESR Minimum Disease Activity: Month 3364.8
JADAS-27 ESR Minimum Disease Activity: Month 3669.6
JADAS-27 ESR Minimum Disease Activity: Month 3965.1
JADAS-27 ESR Minimum Disease Activity: Month 4269.3
JADAS-27 ESR Minimum Disease Activity: Month 4569.7
JADAS-27 ESR Minimum Disease Activity: Month 4869.9
JADAS-27 ESR Minimum Disease Activity: Month 5173.2
JADAS-27 ESR Minimum Disease Activity: Month 5467.2
JADAS-27 ESR Minimum Disease Activity: Month 5772.4
JADAS-27 ESR Minimum Disease Activity: Month 6063.3
JADAS-27 ESR Minimum Disease Activity: Month 6377.8
JADAS-27 ESR Minimum Disease Activity: Month 6674.4
JADAS-27 ESR Minimum Disease Activity: Month 6977.3
JADAS-27 ESR Minimum Disease Activity: Month 7272.1
JADAS-27 ESR Minimum Disease Activity: Month 7572.5
JADAS-27 ESR Minimum Disease Activity: Month 7881.3
SecondaryPercentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Minimum Disease Activity: Month 154.5
JADAS-27 CRP Minimum Disease Activity: Month 335.7
JADAS-27 CRP Minimum Disease Activity: Month 643.8
JADAS-27 CRP Minimum Disease Activity: Month 964.3
JADAS-27 CRP Minimum Disease Activity: Month 1246.7
JADAS-27 CRP Minimum Disease Activity: Month 1569.2
JADAS-27 CRP Minimum Disease Activity: Month 1850.0
JADAS-27 CRP Minimum Disease Activity: Month 2172.7
JADAS-27 CRP Minimum Disease Activity: Month 2463.6
JADAS-27 CRP Minimum Disease Activity: Month 2763.6
JADAS-27 CRP Minimum Disease Activity: Month 3070.0
JADAS-27 CRP Minimum Disease Activity: Month 3363.6
JADAS-27 CRP Minimum Disease Activity: Month 3666.7
JADAS-27 ESR Minimum Disease Activity: Month 154.5
JADAS-27 ESR Minimum Disease Activity: Month 335.7
JADAS-27 ESR Minimum Disease Activity: Month 637.5
JADAS-27 ESR Minimum Disease Activity: Month 957.1
JADAS-27 ESR Minimum Disease Activity: Month 1246.7
JADAS-27 ESR Minimum Disease Activity: Month 1569.2
JADAS-27 ESR Minimum Disease Activity: Month 1850.0
JADAS-27 ESR Minimum Disease Activity: Month 2166.7
JADAS-27 ESR Minimum Disease Activity: Month 2463.6
JADAS-27 ESR Minimum Disease Activity: Month 2760.0
JADAS-27 ESR Minimum Disease Activity: Month 3060.0
JADAS-27 ESR Minimum Disease Activity: Month 3363.6
JADAS-27 ESR Minimum Disease Activity: Month 3666.7
SecondaryPercentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease(27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). Overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of:\<=3.8. For participants with oligoarthritis (\<=4 active joints) minimal disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=2.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Minimum Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Minimum Disease Activity: Month 166.7
JADAS-27 CRP Minimum Disease Activity: Month 364.3
JADAS-27 CRP Minimum Disease Activity: Month 666.7
JADAS-27 CRP Minimum Disease Activity: Month 960.0
JADAS-27 CRP Minimum Disease Activity: Month 1280.0
JADAS-27 CRP Minimum Disease Activity: Month 1566.7
JADAS-27 CRP Minimum Disease Activity: Month 1861.5
JADAS-27 CRP Minimum Disease Activity: Month 2158.3
JADAS-27 CRP Minimum Disease Activity: Month 2481.8
JADAS-27 CRP Minimum Disease Activity: Month 2781.8
JADAS-27 CRP Minimum Disease Activity: Month 3075.0
JADAS-27 CRP Minimum Disease Activity: Month 3363.6
JADAS-27 CRP Minimum Disease Activity: Month 3655.6
JADAS-27 ESR Minimum Disease Activity: Month 171.4
JADAS-27 ESR Minimum Disease Activity: Month 369.2
JADAS-27 ESR Minimum Disease Activity: Month 666.7
JADAS-27 ESR Minimum Disease Activity: Month 960.0
JADAS-27 ESR Minimum Disease Activity: Month 1280.0
JADAS-27 ESR Minimum Disease Activity: Month 1566.7
JADAS-27 ESR Minimum Disease Activity: Month 1861.5
JADAS-27 ESR Minimum Disease Activity: Month 2163.6
JADAS-27 ESR Minimum Disease Activity: Month 2480.0
JADAS-27 ESR Minimum Disease Activity: Month 2791.7
JADAS-27 ESR Minimum Disease Activity: Month 3075.0
JADAS-27 ESR Minimum Disease Activity: Month 3363.6
JADAS-27 ESR Minimum Disease Activity: Month 3655.6
SecondaryPercentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Inactive Disease Activity: Month 124.7
JADAS-27 CRP Inactive Disease Activity: Month 330.9
JADAS-27 CRP Inactive Disease Activity: Month 630.8
JADAS-27 CRP Inactive Disease Activity: Month 928.9
JADAS-27 CRP Inactive Disease Activity: Month 1228.8
JADAS-27 CRP Inactive Disease Activity: Month 1529.8
JADAS-27 CRP Inactive Disease Activity: Month 1839.5
JADAS-27 CRP Inactive Disease Activity: Month 2132.1
JADAS-27 CRP Inactive Disease Activity: Month 2433.3
JADAS-27 CRP Inactive Disease Activity: Month 2730.4
JADAS-27 CRP Inactive Disease Activity: Month 3041.2
JADAS-27 CRP Inactive Disease Activity: Month 3327.3
JADAS-27 CRP Inactive Disease Activity: Month 3633.3
JADAS-27 ESR Inactive Disease Activity: Month 127.4
JADAS-27 ESR Inactive Disease Activity: Month 337.8
JADAS-27 ESR Inactive Disease Activity: Month 634.6
JADAS-27 ESR Inactive Disease Activity: Month 931.6
JADAS-27 ESR Inactive Disease Activity: Month 1224.1
JADAS-27 ESR Inactive Disease Activity: Month 1529.8
JADAS-27 ESR Inactive Disease Activity: Month 1839.5
JADAS-27 ESR Inactive Disease Activity: Month 2134.5
JADAS-27 ESR Inactive Disease Activity: Month 2433.3
JADAS-27 ESR Inactive Disease Activity: Month 2737.5
JADAS-27 ESR Inactive Disease Activity: Month 3035.3
JADAS-27 ESR Inactive Disease Activity: Month 3325.0
JADAS-27 ESR Inactive Disease Activity: Month 3622.2
SecondaryPercentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Inactive Disease Activity: Month 124.3
JADAS-27 CRP Inactive Disease Activity: Month 331.5
JADAS-27 CRP Inactive Disease Activity: Month 630.6
JADAS-27 CRP Inactive Disease Activity: Month 927.5
JADAS-27 CRP Inactive Disease Activity: Month 1225.0
JADAS-27 CRP Inactive Disease Activity: Month 1533.3
JADAS-27 CRP Inactive Disease Activity: Month 1840.6
JADAS-27 CRP Inactive Disease Activity: Month 2136.4
JADAS-27 CRP Inactive Disease Activity: Month 2438.1
JADAS-27 CRP Inactive Disease Activity: Month 2738.9
JADAS-27 CRP Inactive Disease Activity: Month 3046.2
JADAS-27 CRP Inactive Disease Activity: Month 3342.9
JADAS-27 CRP Inactive Disease Activity: Month 3660.0
JADAS-27 ESR Inactive Disease Activity: Month 127.3
JADAS-27 ESR Inactive Disease Activity: Month 339.2
JADAS-27 ESR Inactive Disease Activity: Month 634.7
JADAS-27 ESR Inactive Disease Activity: Month 931.9
JADAS-27 ESR Inactive Disease Activity: Month 1223.5
JADAS-27 ESR Inactive Disease Activity: Month 1533.3
JADAS-27 ESR Inactive Disease Activity: Month 1841.9
JADAS-27 ESR Inactive Disease Activity: Month 2139.1
JADAS-27 ESR Inactive Disease Activity: Month 2438.1
JADAS-27 ESR Inactive Disease Activity: Month 2742.1
JADAS-27 ESR Inactive Disease Activity: Month 3046.2
JADAS-27 ESR Inactive Disease Activity: Month 3337.5
JADAS-27 ESR Inactive Disease Activity: Month 3640.0
SecondaryPercentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1,3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and ESR Score at Months 1,3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75 and 78:Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Inactive Disease Activity: Month 128.8
JADAS-27 CRP Inactive Disease Activity: Month 335.3
JADAS-27 CRP Inactive Disease Activity: Month 636.4
JADAS-27 CRP Inactive Disease Activity: Month 938.5
JADAS-27 CRP Inactive Disease Activity: Month 1236.9
JADAS-27 CRP Inactive Disease Activity: Month 1537.3
JADAS-27 CRP Inactive Disease Activity: Month 1840.0
JADAS-27 CRP Inactive Disease Activity: Month 2137.5
JADAS-27 CRP Inactive Disease Activity: Month 2438.4
JADAS-27 CRP Inactive Disease Activity: Month 2743.0
JADAS-27 CRP Inactive Disease Activity: Month 3047.7
JADAS-27 CRP Inactive Disease Activity: Month 3343.8
JADAS-27 CRP Inactive Disease Activity: Month 3645.5
JADAS-27 CRP Inactive Disease Activity: Month 3941.1
JADAS-27 CRP Inactive Disease Activity: Month 4247.5
JADAS-27 CRP Inactive Disease Activity: Month 4551.1
JADAS-27 CRP Inactive Disease Activity: Month 4843.9
JADAS-27 CRP Inactive Disease Activity: Month 5145.1
JADAS-27 CRP Inactive Disease Activity: Month 5446.7
JADAS-27 CRP Inactive Disease Activity: Month 5748.3
JADAS-27 CRP Inactive Disease Activity: Month 6046.9
JADAS-27 CRP Inactive Disease Activity: Month 6354.5
JADAS-27 CRP Inactive Disease Activity: Month 6644.2
JADAS-27 CRP Inactive Disease Activity: Month 6951.2
JADAS-27 CRP Inactive Disease Activity: Month 7252.4
JADAS-27 CRP Inactive Disease Activity: Month 7548.6
JADAS-27 CRP Inactive Disease Activity: Month 7850.0
JADAS-27 ESR Inactive Disease Activity: Month 128.3
JADAS-27 ESR Inactive Disease Activity: Month 334.3
JADAS-27 ESR Inactive Disease Activity: Month 637.5
JADAS-27 ESR Inactive Disease Activity: Month 936.4
JADAS-27 ESR Inactive Disease Activity: Month 1233.1
JADAS-27 ESR Inactive Disease Activity: Month 1540.6
JADAS-27 ESR Inactive Disease Activity: Month 1839.2
JADAS-27 ESR Inactive Disease Activity: Month 2137.9
JADAS-27 ESR Inactive Disease Activity: Month 2438.7
JADAS-27 ESR Inactive Disease Activity: Month 2747.2
JADAS-27 ESR Inactive Disease Activity: Month 3045.9
JADAS-27 ESR Inactive Disease Activity: Month 3343.5
JADAS-27 ESR Inactive Disease Activity: Month 3643.8
JADAS-27 ESR Inactive Disease Activity: Month 3941.5
JADAS-27 ESR Inactive Disease Activity: Month 4245.5
JADAS-27 ESR Inactive Disease Activity: Month 4548.3
JADAS-27 ESR Inactive Disease Activity: Month 4841.0
JADAS-27 ESR Inactive Disease Activity: Month 5147.9
JADAS-27 ESR Inactive Disease Activity: Month 5444.3
JADAS-27 ESR Inactive Disease Activity: Month 5744.8
JADAS-27 ESR Inactive Disease Activity: Month 6042.9
JADAS-27 ESR Inactive Disease Activity: Month 6357.8
JADAS-27 ESR Inactive Disease Activity: Month 6641.9
JADAS-27 ESR Inactive Disease Activity: Month 6950.0
JADAS-27 ESR Inactive Disease Activity: Month 7251.2
JADAS-27 ESR Inactive Disease Activity: Month 7550.0
JADAS-27 ESR Inactive Disease Activity: Month 7853.1
SecondaryPercentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Inactive Disease Activity: Month 136.4
JADAS-27 CRP Inactive Disease Activity: Month 314.3
JADAS-27 CRP Inactive Disease Activity: Month 631.3
JADAS-27 CRP Inactive Disease Activity: Month 928.6
JADAS-27 CRP Inactive Disease Activity: Month 1240.0
JADAS-27 CRP Inactive Disease Activity: Month 1515.4
JADAS-27 CRP Inactive Disease Activity: Month 1833.3
JADAS-27 CRP Inactive Disease Activity: Month 2136.4
JADAS-27 CRP Inactive Disease Activity: Month 2427.3
JADAS-27 CRP Inactive Disease Activity: Month 2718.2
JADAS-27 CRP Inactive Disease Activity: Month 3020.0
JADAS-27 CRP Inactive Disease Activity: Month 3327.3
JADAS-27 CRP Inactive Disease Activity: Month 3616.7
JADAS-27 ESR Inactive Disease Activity: Month 127.3
JADAS-27 ESR Inactive Disease Activity: Month 314.3
JADAS-27 ESR Inactive Disease Activity: Month 625.0
JADAS-27 ESR Inactive Disease Activity: Month 921.4
JADAS-27 ESR Inactive Disease Activity: Month 1233.3
JADAS-27 ESR Inactive Disease Activity: Month 1523.1
JADAS-27 ESR Inactive Disease Activity: Month 1833.3
JADAS-27 ESR Inactive Disease Activity: Month 2133.3
JADAS-27 ESR Inactive Disease Activity: Month 2436.4
JADAS-27 ESR Inactive Disease Activity: Month 2710.0
JADAS-27 ESR Inactive Disease Activity: Month 3020.0
JADAS-27 ESR Inactive Disease Activity: Month 3327.3
JADAS-27 ESR Inactive Disease Activity: Month 3616.7
SecondaryPercentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set

JADAS-27 was a validated composite disease activity measure for JIA. JADAS-27 CRP score and JADAS-27 ESR score was based on four components: physician global assessment of disease activity assessed on a VAS with score range from 0 (no disease activity) to 10 (maximum disease activity); parent/legal guardian/participant evaluation of overall well-being using CHAQ (0 \[very well\] to 10 \[very poor\]); number of joints with active disease (27 joint assessment ranging from 0 to 27) and CRP or ESR (value normalized to 0 to 10 scale). The overall JADAS-27 score was sum of 4 components and it ranged from 0 to 57. A higher score indicated more disease activity. For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score and JADAS-27 ESR score of \<=1.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants With JADAS Inactive Disease Activity Calculated From JADAS-27 CRP and JADAS-27 ESR Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
JADAS-27 CRP Inactive Disease Activity: Month 126.7
JADAS-27 CRP Inactive Disease Activity: Month 335.7
JADAS-27 CRP Inactive Disease Activity: Month 653.3
JADAS-27 CRP Inactive Disease Activity: Month 926.7
JADAS-27 CRP Inactive Disease Activity: Month 1253.3
JADAS-27 CRP Inactive Disease Activity: Month 1526.7
JADAS-27 CRP Inactive Disease Activity: Month 1846.2
JADAS-27 CRP Inactive Disease Activity: Month 2141.7
JADAS-27 CRP Inactive Disease Activity: Month 2445.5
JADAS-27 CRP Inactive Disease Activity: Month 2745.5
JADAS-27 CRP Inactive Disease Activity: Month 3058.3
JADAS-27 CRP Inactive Disease Activity: Month 3354.5
JADAS-27 CRP Inactive Disease Activity: Month 3633.3
JADAS-27 ESR Inactive Disease Activity: Month 135.7
JADAS-27 ESR Inactive Disease Activity: Month 338.5
JADAS-27 ESR Inactive Disease Activity: Month 646.7
JADAS-27 ESR Inactive Disease Activity: Month 926.7
JADAS-27 ESR Inactive Disease Activity: Month 1240.0
JADAS-27 ESR Inactive Disease Activity: Month 1526.7
JADAS-27 ESR Inactive Disease Activity: Month 1838.5
JADAS-27 ESR Inactive Disease Activity: Month 2145.5
JADAS-27 ESR Inactive Disease Activity: Month 2440.0
JADAS-27 ESR Inactive Disease Activity: Month 2741.7
JADAS-27 ESR Inactive Disease Activity: Month 3058.3
JADAS-27 ESR Inactive Disease Activity: Month 3345.5
JADAS-27 ESR Inactive Disease Activity: Month 3633.3
SecondaryPercentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA1 Analysis Set

Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, methotrexate (MTX)/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

Time frame:
From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Oral corticosteroids: Eligibility of tapering12.05
Oral corticosteroids: Partial tapering success among all3.61
Oral corticosteroids: Complete tapering success among all8.43
Oral corticosteroids: Partial tapering success among eligible30.00
Oral corticosteroids: Complete tapering success among eligible70.00
Methotrexate/Leflunomide: Eligibility of tapering3.61
Methotrexate/Leflunomide: Partial tapering success among all0
Methotrexate/Leflunomide: Complete tapering success among all1.20
Methotrexate/Leflunomide: Partial tapering success among eligible0
Methotrexate/Leflunomide: Complete tapering success among eligible33.33
Tofacitinib: Eligibility of tapering3.61
Tofacitinib: Partial tapering success among all0
Tofacitinib: Complete tapering success among all3.61
Tofacitinib: Partial tapering success among eligible0
Tofacitinib: Complete tapering success among eligible100
SecondaryPercentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA2 Analysis Set

Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

Time frame:
From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Oral corticosteroids: Eligibility of tapering10.39
Oral corticosteroids: Partial tapering success among all3.90
Oral corticosteroids: Complete tapering success among all6.49
Oral corticosteroids: Partial tapering success among eligible37.50
Oral corticosteroids: Complete tapering success among eligible62.50
Methotrexate/Leflunomide: Eligibility of tapering3.90
Methotrexate/Leflunomide: Partial tapering success among all0
Methotrexate/Leflunomide: Complete tapering success among all1.30
Methotrexate/Leflunomide: Partial tapering success among eligible0
Methotrexate/Leflunomide: Complete tapering success among eligible33.33
Tofacitinib: Eligibility of tapering3.90
Tofacitinib: Partial tapering success among all0
Tofacitinib: Complete tapering success among all3.90
Tofacitinib: Partial tapering success among eligible0
Tofacitinib: Complete tapering success among eligible100
SecondaryPercentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in pJIA Analysis Set

Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

Time frame:
From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in pJIA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Oral corticosteroids: Eligibility of tapering8.90
Oral corticosteroids: Partial tapering success among all2.05
Oral corticosteroids: Complete tapering success among all6.85
Oral corticosteroids: Partial tapering success among eligible23.08
Oral corticosteroids: Complete tapering success among eligible76.92
Methotrexate/Leflunomide: Eligibility of tapering12.93
Methotrexate/Leflunomide: Partial tapering success among all2.04
Methotrexate/Leflunomide: Complete tapering success among all10.20
Methotrexate/Leflunomide: Partial tapering success among eligible15.79
Methotrexate/Leflunomide: Complete tapering success among eligible78.95
Tofacitinib: Eligibility of tapering4.76
Tofacitinib: Partial tapering success among all2.04
Tofacitinib: Complete tapering success among all1.36
Tofacitinib: Partial tapering success among eligible42.86
Tofacitinib: Complete tapering success among eligible28.57
SecondaryPercentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in ERA Analysis Set

Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

Time frame:
From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in ERA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Oral corticosteroids: Eligibility of tapering0
Oral corticosteroids: Partial tapering success among all0
Oral corticosteroids: Complete tapering success among all0
Methotrexate/Leflunomide: Eligibility of tapering7.69
Methotrexate/Leflunomide: Partial tapering success among all0
Methotrexate/Leflunomide: Complete tapering success among all7.69
Methotrexate/Leflunomide: Partial tapering success among eligible0
Methotrexate/Leflunomide: Complete tapering success among eligible100
Tofacitinib: Eligibility of tapering7.69
Tofacitinib: Partial tapering success among all7.69
Tofacitinib: Complete tapering success among all0
Tofacitinib: Partial tapering success among eligible100
Tofacitinib: Complete tapering success among eligible0
SecondaryPercentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in PsA Analysis Set

Participants with inactive disease for at least 24 consecutive weeks began to taper off concomitant JIA therapies and tofacitinib. Tapering of therapies was completed in the following order: oral corticosteroids, MTX/leflunomide, tofacitinib. A participant had multiple taperings with different results per medication and the best tapering result per medication per participant is summarized in this outcome measure. Participants achieving eligibility of tapering = participants who took the drug and started tapering; participants achieving partial tapering = participants who were able to undergo tapering from one dose level to a lower dose level; participants achieving complete tapering = participants discontinued drug completely.

Time frame:
From 24 Weeks up to the last dose of the study drug (maximum follow up to 117 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Tapering of Oral Corticosteroids, Methotrexate/Leflunomide, and Tofacitinib: Participants in PsA Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
Oral corticosteroids: Eligibility of tapering6.67
Oral corticosteroids: Partial tapering success among all0
Oral corticosteroids: Complete tapering success among all6.67
Oral corticosteroids: Partial tapering success among eligible0
Oral corticosteroids: Complete tapering success among eligible100
Methotrexate/Leflunomide: Eligibility of tapering13.33
Methotrexate/Leflunomide: Partial tapering success among all0
Methotrexate/Leflunomide: Complete tapering success among all13.33
Methotrexate/Leflunomide: Partial tapering success among eligible0
Methotrexate/Leflunomide: Complete tapering success among eligible100
Tofacitinib: Eligibility of tapering6.67
Tofacitinib: Partial tapering success among all0
Tofacitinib: Complete tapering success among all6.67
Tofacitinib: Partial tapering success among eligible0
Tofacitinib: Complete tapering success among eligible100
SecondaryPercentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set

Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA1 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
At Month 195.35
At Month 397.59
At Month 6100
At Month 997.44
At Month 12100
At Month 1597.96
At Month 1894.87
At Month 21100
At Month 24100
At Month 27100
At Month 30100
At Month 33100
At Month 36100
SecondaryPercentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set

Absence of fever was defined as absence of fever due to sJIA in the week preceding the assessment at each visit. Fever was defined as temperature \>38 C/ 100.4 F (oral) or \>101.4 F/38.6 C (rectal), due to sJIA, in the last 7 days before the visit.

Time frame:
At Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Absence of Fever 1 Week Prior to Assessment at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36: Participants in sJIA2 Analysis Set
Percentage of participantsTofacitinib 5 mg BID (Open-label)
At Month 194.81
At Month 397.30
At Month 6100
At Month 997.14
At Month 12100
At Month 1597.56
At Month 1893.75
At Month 21100
At Month 24100
At Month 27100
At Month 30100
At Month 33100
At Month 36100
SecondaryChange From Baseline in Tender Entheseal Assessment at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

Tender entheseal assessment was performed by the investigator as 'Yes' or 'No'. 'Yes' indicated the presence of tenderness upon firm palpation over the specified enthesis and 'No' indicated the absence of tenderness upon firm palpation over the indicated enthesis. A total of 16 entheseal sites were assessed and the number of tender sites was counted. The score ranges from 0 to 16, where 0 represents the best possible outcome (no tenderness) and 16 represents the worst possible outcome (maximum tenderness).

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Tender Entheseal Assessment at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 3-4.47 ± 4.82
Change at Month 6-4.83 ± 5.08
Change at Month 12-4.33 ± 4.70
Change at Month 18-5.08 ± 5.16
Change at Month 24-5.33 ± 4.38
Change at Month 30-4.75 ± 5.50
Change at Month 36-4.83 ± 4.78
SecondaryChange From Baseline in Modified Schober's Test at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

Modified Schober's test was performed at the study visits only in participants with enthesitis-related arthritis. With the participant standing erect and with feet together, a line joining the posterior superior iliac spines (the dimples of Venus) was used as a landmark for the lumbosacral junction. A mark was made 5 centimeters (cm) below and 10 cm above the lumbosacral junction. With the participant in maximum forward flexion with the knees straight, the investigator measures the distance between the two marks in centimeters. The full measurement between the two lines was recorded to the nearest tenth of a centimeter (e.g., 15.2 cm) on the appropriate CRF.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Centimeters
Change From Baseline in Modified Schober's Test at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
CentimetersTofacitinib 5 mg BID (Open-label)
Change at Month 30.37 ± 1.14
Change at Month 60.34 ± 1.15
Change at Month 120.20 ± 1.21
Change at Month 180.29 ± 1.30
Change at Month 240.09 ± 1.32
Change at Month 30-0.87 ± 2.29
Change at Month 360.13 ± 1.82
SecondaryChange From Baseline in Overall Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

Severity of overall back pain (at any time) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Overall Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 3-3.18 ± 2.57
Change at Month 6-2.78 ± 2.29
Change at Month 12-3.57 ± 2.57
Change at Month 18-3.83 ± 2.45
Change at Month 24-3.70 ± 2.82
Change at Month 30-3.11 ± 3.29
Change at Month 36-3.46 ± 3.14
SecondaryChange From Baseline in Nocturnal Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set

Severity of nocturnal back pain (at night) experienced was rated by parent/legal guardian/participant on a VAS from 0 (no pain) to 10 (most severe pain), where higher score indicated more severe pain.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Nocturnal Back Pain at Months 3, 6, 12, 18, 24, 30 and 36: Participants in ERA Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 3-2.16 ± 2.56
Change at Month 6-1.78 ± 2.62
Change at Month 12-2.67 ± 2.18
Change at Month 18-3.04 ± 2.52
Change at Month 24-3.10 ± 2.53
Change at Month 30-2.44 ± 2.67
Change at Month 36-2.58 ± 3.11
SecondaryChange From Baseline in Body Surface Area (BSA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set

BSA was measured as the percentage of BSA affected by psoriasis using the palm method; the participants palm was used for the calculation. One of the participant's palm to proximal interphalangeal (PIP) and thumb equals to 1% of BSA. Regions of the body included along with percentage of BSA: 1) head and neck = 10% (10 palms); 2) upper extremities = 20% (20 palms); 3) trunk (axillae and groin) = 30% (30 palms) and 4) lower extremities (buttocks) = 40% (40 palms).Total BSA was sum of all regions ranged from 0% to 100% (100 palms). The physician assessed the total BSA affected by psoriasis using the addition of the individual regions.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Percentage of BSA
Change From Baseline in Body Surface Area (BSA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set
Percentage of BSATofacitinib 5 mg BID (Open-label)
Change at Month 3-1.81 ± 3.66
Change at Month 6-2.03 ± 3.96
Change at Month 12-1.89 ± 3.93
Change at Month 18-1.73 ± 4.86
Change at Month 24-2.00 ± 5.42
Change at Month 30-1.77 ± 4.14
Change at Month 36-1.53 ± 2.51
SecondaryChange From Baseline in Physician's Global Assessment (PGA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set

PGA was used to determine participant's overall psoriasis lesions at a given time point. Overall lesions were graded for induration, erythema, and scaling based upon scales. Induration scale ranged from: 0 (no evidence of plaque elevation) to 5 (severe plaque elevation or more); erythema scale ranged from: 0 (no evidence of erythema, hyper pigmentation may be present) to 5 (dusky to deep red coloration); scaling scale ranged from: 0 (no evidence of scaling) to 5 (severe; very thick tenacious scale predominates). Total PGA score was calculated based on sum of 3 scales divided by 3 to obtain final PGA, ranging from 0 (no evidence) to 5 (maximum severity); higher scores indicated more severity of psoriasis.

Time frame:
Baseline (from the qualifying study or the extension study based on the enrollment gap); at Months 3, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · Score on a scale
Change From Baseline in Physician's Global Assessment (PGA) at Months 3, 6, 12, 18, 24, 30 and 36: Participants in PsA Analysis Set
Score on a scaleTofacitinib 5 mg BID (Open-label)
Change at Month 3-0.56 ± 1.26
Change at Month 6-0.60 ± 1.24
Change at Month 12-0.71 ± 1.20
Change at Month 18-0.67 ± 1.30
Change at Month 24-0.64 ± 1.50
Change at Month 30-0.69 ± 1.03
Change at Month 36-0.44 ± 1.01

Adverse events

Collected over From start of the study intervention up to 28 days after last dose of the study intervention or until study completion or withdrawal, whichever is longer (maximum up to 118 months from start of study intervention). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID (Open-label)2/302 (0.7%)48/302 (15.9%)242/302 (80.1%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventTofacitinib 5 mg BID (Open-label)
Still's diseaseMusculoskeletal and connective tissue disorders8/302
Suicidal ideationPsychiatric disorders5/302
Herpes zosterInfections and infestations4/302
PyrexiaGeneral disorders3/302
Appendicitis noninfectiveGastrointestinal disorders2/302
Haemophagocytic lymphohistiocytosisImmune system disorders2/302
PneumoniaInfections and infestations2/302
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders2/302
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/302
Suicide attemptPsychiatric disorders2/302
Most frequent other events
Showing 10 of 48
Most frequent other events
EventTofacitinib 5 mg BID (Open-label)
Upper respiratory tract infectionInfections and infestations66/302
NasopharyngitisInfections and infestations40/302
Urinary tract infectionInfections and infestations29/302
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders29/302
Viral infectionInfections and infestations27/302
PyrexiaGeneral disorders25/302
ArthralgiaMusculoskeletal and connective tissue disorders25/302
Abdominal painGastrointestinal disorders23/302
HeadacheNervous system disorders22/302
VomitingGastrointestinal disorders20/302

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tofacitinib 5 mg BID (Open-label)
Mean11.86 ± 4.38
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BID (Open-label)
Female202
Male100
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tofacitinib 5 mg BID (Open-label)
American Indian or Alaska Native0
Asian37
Native Hawaiian or Other Pacific Islander0
Black or African American11
White229
More than one race0
Unknown or Not Reported25
08

Study locations

104 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Loma Linda University Children'S Hospital
    Loma Linda, California 92354, United States
  • Loma Linda University Clinical Trials Center
    Loma Linda, California 92354, United States
  • Loma Linda University Eye Institute
    Loma Linda, California 92354, United States
  • Loma Linda University General Pediatric Clinic - Meridian
    Loma Linda, California 92354, United States
  • Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology)
    Loma Linda, California 92408, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology)
    San Bernardino, California 92408, United States
  • Rady Children's Hospital Center for Pediatric Clinical Research
    San Diego, California 92123, United States
  • Rady Children's Hospital Rheumatology Clinic
    San Diego, California 92123, United States
  • Rady Children's Hospital San Diego- Education and Office Building
    San Diego, California 92123, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Rady Children's Research Pharmacy
    San Diego, California 92123, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • IDS Pharmacy
    Washington D.C., District of Columbia 20010, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Center for Advanced Pediatrics
    Atlanta, Georgia 30329, United States
  • AU Medical Center
    Augusta, Georgia 30912, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • Tufts Medical Center - Floating Hospital for Children
    Boston, Massachusetts 02111, United States
  • Explorer Clinic, University of Minnesota Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Cohen Children's Medical Center of New York
    Lake Success, New York 11042, United States
  • Columbia University Medical Center-Herbert Irving Pavillion
    New York, New York 10032, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Pediatric Research
    Charlotte, North Carolina 20207, United States
  • Levine Children's Specialty Center
    Charlotte, North Carolina 28203, United States
  • Atrium Health- Investigational Drug Services
    Charlotte, North Carolina 28207, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Randall Children's Hospital at Legacy Emanuel
    Portland, Oregon 97227, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Dell Children's Medical Group, Dell Children's Medical Center
    Austin, Texas 78723, United States
  • Texas Children's Hospital- Clinical Care Center
    Houston, Texas 77030, United States
  • Texas Children's Hospital- Clinical Research Center
    Houston, Texas 77030, United States
  • Texas Children's Hospital- Investigational Pharmacy
    Houston, Texas 77030, United States
  • Texas Children's Hospital- Main Hospital
    Houston, Texas 77030, United States
  • Texas Children's Hospital/Baylor College of Medicine- Feigin Center
    Houston, Texas 77030, United States
  • Intermountain - Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Instituto CAICI SRL
    Rosario, Santa Fe Province S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Hospital Britanico de Buenos Aires
    CABA, C1280AEB, Argentina
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven - Gasthuisberg
    Leuven, 3000, Belgium
  • SER - Serviços Especializados em Reumatologia
    Salvador, Estado de Bahia 40150-150, Brazil
  • CMIP - Centro Mineiro de Pesquisa Ltda
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Hospital Pequeno Príncipe Clinical Research Office
    Curitiba, Paraná 80250-060, Brazil
  • Faculdade de Medicina da UNESP
    Botucatu, São Paulo 18618-686, Brazil
  • Instituto de Puericultura e Pediatria Martagao Gesteira (IPPMG)
    Rio de Janeiro, 21941-912, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina
    São Paulo, 04037-002, Brazil
  • Instituto da Crianca do Hospital das Clinicas da FMUSP
    São Paulo, 05409-011, Brazil
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • McGill University Health Center, Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Children's Hospital of Soochow University
    Suzhou, Jiangsu 215003, China
  • The Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310057, China
  • Beijing Children's Hospital, Capital Medical University/Rheumatology Department
    Beijing, 100045, China
  • PRI - Pediatric Rheumatology Research Institute GmbH
    Bad Bramstedt, 24576, Germany
  • Hamburger Zentrum fur Kinder und Jugendrheumatologie
    Hamburg, 22081, Germany
  • Asklepios Klinik Sankt Augustin GmbH
    Sankt Augustin, 53757, Germany
  • St. Josef-Stift Sendenhorst
    Sendenhorst, 48324, Germany
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • Institute of Child Health
    Kolkata, West Bengal 700017, India
  • Institute of Post Graduate Medical Education and Research & SSKM Hospital
    Kolkata, West Bengal 700020, India
  • Sir Ganga Ram Hospital
    New Delhi, 110060, India
  • Rambam Health Care Campus
    Haifa, 31096 01, Israel
  • Meir Medical Center - Pediatric Clinic
    Kfar Saba, 4428164, Israel
  • Chaim Sheba M.C Tel hashomer
    Ramat Gan, 52621, Israel
  • Clínica de Investigacion en Reumatologia y Obesidad, S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo León 64460, Mexico
  • Centro de Alta Especialidad de Reumatología e Investigación del Potosí, S.C.
    San Luis de Potosí, 78213, Mexico
  • Hospital Central "Dr. Ignacio Morones Prieto"
    San Luis Potosí City, 78290, Mexico
  • Unidad de Investigaciones Reumatologicas A.C.
    San Luis Potosí City, 78290, Mexico
  • Wojewodzki Szpital Dzieciecy im. J. Brudzinskiego
    Bydgoszcz, 85-667, Poland
  • Wojewodzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie
    Krakow, 31-503, Poland
  • Klinika Kardiologii i Reumatologii Dzieciecej
    Lodz, 91-738, Poland
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warsaw, 02-637, Poland
  • FSBEI HE BSMU MoH RF
    Ufa, Bashkortostan Republic 450008, Russia
  • Clinic of FSBEI HE BSMU MoH RF
    Ufa, Bashkortostan Republic 450083, Russia
  • Federal State Budgetary Scientific Institution
    Moscow, 115522, Russia
  • FSAEI HE I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University)
    Moscow, 119435, Russia
  • FSAEI HE I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University),
    Moscow, 119991, Russia
  • FSAI "NMRCCH" of MOH Russia
    Moscow, 119991, Russia
  • FSBEI HE "St. Petersburg State Pediatric Medical University" of the Ministry of Healthcare
    Saint Petersburg, 194100, Russia
  • State Budgetary Healthcare Institution of Samara Region "Tolyatti City Clinical Hospital #5"
    Tolyatti, 445039, Russia
  • Narodny ustav reumatickych chorob
    Piešťany, 921 12, Slovakia
  • Panorama Medical Centre
    Panorama, CAPE TOWN 7500, South Africa
  • Durban International Clinical Research Site, Enhancing Care Foundation
    Durban, 4301, South Africa
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, 46026, Spain
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey (Türkiye)
  • Umraniye Training and Research Hospital
    Istanbul, 34764, Turkey (Türkiye)
  • Istanbul Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi Cocuk Romatoloji Bolumu
    Kadikoy / Istanbul, 34722, Turkey (Türkiye)

Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, Cuttica R, De La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert GS, Neiva C, Rivas-Chacon R, Rizo Rodriguez JC, Vazquez-Del Mercado M, Wagner-Weiner L, Weiss JE, Wouters C, Posner H, Wouters A, Chang C, White C, Kanik K, Liu S, Martini A, Lovell DJ, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21;83(11):1561-1571. doi: 10.1136/ard-2023-225094. PubMed 38849152 ↗
  • Chang C, Vong C, Wang X, Hazra A, Diehl A, Nicholas T, Mukherjee A. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):599-611. doi: 10.1002/psp4.13104. Epub 2024 Jan 31. PubMed 38298058 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Feb 2025, 142 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Dec 28, 2011
StartActual
Mar 18, 2013
Primary completionActual
Feb 12, 2025
CompletionActual
Feb 12, 2025
Results first posted
Mar 23, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01500551
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 28, 2011
Start date
Mar 18, 2013
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Results posted
Mar 23, 2026
Last update
Mar 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion